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ABSTRACT 
 
Despite many novel therapeutic approaches, breast cancer remains one 
of the leading cause of cancer mortality among women. Recent findings 
indicate that cancer-associated fibroblasts (CAFs), the major components of the 
tumor microenvironment, play a crucial role in breast cancer progression, but 
how they promote tumorigenesis is poorly understood. Increasing evidence 
indicates that exosomes, membrane vesicles sized 30-100 nm in diameter, play 
an important role in cell-cell communication. Exosomes and their cargo, 
including microRNAs (miRs), may vehicolate between cells and affect the 
biological behavior of recipient cells. Therefore, one alternative mechanism of 
the promotion of breast cancer progression by CAFs may be through cancer-
associated fibroblast-secreted exosomes, which would deliver oncogenic miRs 
to breast cancer cells. Firstly, to investigate the potential role of miRs in 
stroma-tumor communication, we compared miR expression profile in 
exosomes from 2 cancer-associated fibroblasts and 2 normal fibroblasts. We 
found that in CAF exosomes the levels of miR-21, miR-378e, and miR-143 
were increased as compared to normal fibroblast exosomes, and we validated 
the array data by real-time PCR. By immunofluorescence experiments, we 
demonstrated that PKH26-labeled-exosomes could be transferred from 
fibroblasts to a breast cancer epithelial cell line, T47D. Furthermore, to 
elucidate whether the identified miRs were shuttled into T47D cells via 
exosomes, we transfected CAFs with cy3-labeled-miRs (cy3-miR-21, cy3-
miR-143, cy3-miR-378e), and, then, we isolated the released exosomes. 
Interestingly, when these exosomes were added to T47D cells, the cy3-miRs 
were detected in the cytoplasm of T47D cells, and they co-localized with the 
signals of an exosomal marker, CD63. Then, we demonstrated that TGF-β, 
apart from its direct role in the activation of normal fibroblasts to CAFs, 
increased the levels of these miRs in normal fibroblast exosomes. Finally, for 
the first time, we provided evidence of the role of CAF exosomes and their 
miR contents in the induction of stemness phenotype in T47D cells. In fact, 
T47D cells exposed to CAF exosomes or transfected with the identified miRs 
exhibited a significantly increased capacity to form mammospheres, and 
increased stem cell and epithelial-mesenchymal transition markers, SOX2, 
Nanog, Oct3/4, Snail and Zeb. We conclude that CAFs regulate the stemness 
phenotype of breast cancer cells through exosome-mediated delivery of 
oncogenic miRs. Our data provide insight into the mechanisms underlying the 
stemness maintenance in breast cancer.  
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1. BACKGROUND 
 
1.1 Breast cancer 
 
 
 
1.1.1 Breast cancer: risk factors and incidence 
Breast cancer (BC) is the most common cancer in women. Aside from 
age, sex, and family history (for instance BRCA1 and BRCA2 mutation 
carriers), risk of developing breast cancer is largely linked to reproductive 
factors, which characterize exposure to sex hormones. Specifically, risk of 
developing breast cancer is increased by early menarche, late menopause, and 
nulliparity, whereas risk is reduced by higher parity and lactation (Anderson et 
al. 2014). Variation in incidence rates worldwide is thought to be due to 
differences in reproductive patterns and other hormonal factors as well as early 
detection. In the United States, BC mortality rates have been decreasing over 
the last 2-3 decades, largely as result of early detection as well as improved 
targeted therapy. Thanks to early detection via mammogram, most of breast 
cancers in developed parts of world are diagnosed in the early stage of the 
disease. Early stage breast cancers can be completely cut by surgery. Over time 
however, the disease may come back even after complete resection, which has 
prompted the development of an adjuvant therapy. Surgery followed by 
adjuvant treatment has been the gold standard for breast cancer treatment for a 
long time (Miller et al. 2014).  
 
 
 
1.1.2 Breast cancer classifications and treatment 
Breast cancer is a heterogeneous disease with a number of 
morphological subtypes. Invasive ductal carcinoma is the most common 
morphological subtype, representing 80% of the invasive breast cancers. 
Invasive lobular carcinoma is the next most common subtype, representing 
approximately 10% of invasive breast cancers. The less common subtypes of 
the invasive breast cancers include: mucinous, cribriform, micropapillary, 
papillary, tubular, medullary, metaplastic, and inflammatory carcinomas 
(Malhotra et al. 2010) (Figure 1). 
Further important breast cancer classifications are the immunohistochemical 
and molecular classifications. In fact, the molecular subtype of breast cancer 
carries important predictive and prognostic values, and, thus, has been 
incorporated in the basic initial process of breast cancer diagnosis.  
Breast cancers can be divided into 5 molecular subtypes: 
- luminal type A and B,  
- human epidermal growth factor receptor 2 (HER2) type,  
 - normal breast-like,  
- basal-like types. 
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Figure 2. Immunohistochemical and molecular classifications of breast cancer 
 
 
Luminal breast cancer (luminal A and luminal B subtypes) responds to 
estrogen (hormonal) manipulation. Standard hormonal therapies include 
aromatase inhibitors (anastrozole, exemestane and letrozole) and ER targeted 
therapy (tamoxifen and fulvestrant). 50% of patients with previously hormonal 
positive breast cancer fail to respond to hormonal manipulation at relapse. It is 
therefore clear that it is important to develop newer treatment strategies to 
overcome this resistance. In terms of hormonal sensitive HER2-positive breast 
cancers this can be achieved with simultaneous targeting of both receptors. 
However, for hormonal sensitive HER2-negative breast cancers, alternative 
approaches are required, such as mammalian target of rapamycin (mTOR) or 
cyclin dependent kinase 4/6 (CDK4/6) inhibitors.  
HER2-positive breast cancers represent approximately 20% of breast cancers 
and confer a poorer prognosis. HER2 targeted therapy with the anti-HER2 
antibody trastuzumab has improved disease free survival and overall survival 
in the adjuvant and metastatic setting. Unfortunately, there is evidence that 
HER2-positive BC becomes resistant to anti-HER2 therapies. Current 
strategies to overcome resistance include blockade with multiple anti-HER2 
antibodies, dual tyrosine kinase inhibitors, and antibody-drug conjugates, alone 
or in combination.  
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12 to 17% of BCs are TNBCs. Eighty-five percent of basal like breast cancers 
and a high proportion of BRCA mutant breast cancers are triple negative. The 
standard palliative treatment of TNBC remains systemic chemotherapy. TNBC 
patients initially respond well to treatment, but these responses lack durability 
resulting in a poorer prognosis. There is, thus, a need to identify new targets for 
this subgroup (Sharp and Harper-Wynne 2014) (Figure 3). 
 
 
 
Figure 3. Breast cancer subtypes and treatment strategies 
 
 
 
1.1.3 Breast cancer stem cells 
Cancer stem cells (CSCs) are rare, tumor-initiating cells that exhibit 
stem cell properties: capacity of self-renewal, pluripotency, highly tumorigenic 
potential, and resistance to therapy (Czerwinska and Kaminska 2015). 
Cancer stem cells have been characterized and isolated from many cancers, 
including breast cancer. The best characterized signaling pathways controlling 
self-renewal and differentiation in normal stem cells, such as Wnt/β-catenin, 
Notch, Hedgehog, and transforming growth factor-β/bone morphogenetic 
protein (TGF-β/BMP) pathways, are frequently deregulated in breast cancer 
cells, which leads to the acquisition of the stem-cell phenotype. Moreover, 
deregulation of these signaling pathways is frequently linked to an epithelial-
mesenchymal transition (EMT), and breast CSCs often possess properties of 
cells that have undergone the EMT process (Mani et al. 2008, Morel et al. 
2008, Pinto et al. 2013). EMT is a process by which epithelial cells attain a 
mesenchymal phenotype, allowing them to break free from the primary tumor 
site and metastasize at distant sites. Thus, EMT signaling is involved in 
development and maintenance of breast CSCs. Furthermore, while 
overexpression of Oct3/4, Sox2, Klf4, and c-myc genes in somatic cells leads 
to dedifferentiation into induced pluripotent stem cells (iPSCs), the activation 
of the molecular targets of these pluripotency-associated genes is frequently 
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observed in poorly differentiated breast tumors and other cancers (Takahashi et 
al. 2006). Notably, accumulating evidence indicates that the expression of 
Oct3/4, Nanog, and Sox2 transcription factors has a strong correlation with 
CSCs: knockdown of these genes decreased tumor sphere formation and 
inhibited tumor formation in xenograft tumor models (Leis et al 2012, Wang et 
al. 2014). In addition, recent studies have elucidated that the expression of 
these factors in CSCs is regulated by epigenetic mechanisms (Munoz et al. 
2012).  
The CSCs have important implications in cancer treatment. Current anti-cancer 
therapy is effective for removing the tumor mass, but often treatment effects 
are transient, thus tumor relapses and metastatic disease occurs. A possible 
explanation is that anti-cancer therapies fail to kill CSCs (Figure 4). Different 
mechanisms could explain breast CSC chemo-resistance: aberrant ABC 
transporter expression/activity, increased aldehyde dehydrogenase activity, 
enhanced DNA damage response, activation of self-renewal signaling 
pathways, and epigenetic deregulations (Kaminska et al. 2013). Moreover, 
CSCs have a slow rate of cell turnover, and, thus, can escape from 
chemotherapeutic agents that target rapidly proliferating cells. However, 
targeting differentiated as well as tumor stem cells is a prerequisite for therapy 
to be efficient. In fact, whereas CSCs can differentiate into non-CSCs giving 
rise to the tumor heterogeneity, non-CSCs could be reprogrammed into CSCs. 
This phenotypic plasticity has implications for cancer treatment: if non-CSCs 
can give rise to CSCs, therapeutic elimination of CSCs may be followed by 
their regeneration from residual non-CSCs, allowing tumor re-growth and 
clinical relapse (Pinto et al. 2013). 
  
 
 
Figure 4. Comparison between conventional therapies and CSC targeted 
therapies 
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1.2 Tumor microenvironment 
 
 
 
1.2.1 The distinctive microenvironments of tumors 
 The neoplastic epithelial cells constitute a compartment, referred to as  
the parenchyma, that is strictly associated to the mesenchymal cells forming 
the tumor-associated stroma. As interactions between cells and their 
microenvironment are crucial for normal tissue homeostasis in physiological 
conditions, also communication between epithelial cells and stroma is 
necessary for tumor initiation and progression. The multiple stromal cell types  
create a succession of tumor microenvironments that change as tumors invade 
normal tissue, and then, seed and colonize distant tissues (Figure 5). This 
histopathological progression must reflect underlying changes in heterotypic 
signaling between tumor parenchyma and stroma. Thus, incipient neoplasias 
begin the interplay by recruiting and activating stromal cell types that assemble 
into an initial pre-neoplastic stroma, which in turn responds reciprocally by 
enhancing the neoplastic phenotypes of the nearby cancer cells. The cancer 
cells, which may further evolve genetically, again feed signals back to the 
stroma, continuing the reprogramming of normal stromal cells; ultimately, 
signals originating in the tumor stroma enable cancer cells to invade normal 
adjacent tissues and disseminate. This model of reciprocal heterotypic 
signaling must be extended to encompass the final stage of multistep tumor 
progression-metastasis. In fact, once reached distant organs, the circulating 
cancer cells that are released from primary tumors encounter a naive, fully 
normal, tissue microenvironment, that they must educate in order to proceed to 
colonize the new site. However, in some cases, certain tissue 
microenvironments, referred as “metastatic niches”, for various reasons, may 
already be supportive of the seeded cancer cells. This permissiveness may be 
intrinsic to the tissue site (Talmadge et al. 2010) or pre-induced by circulating 
factors released by the primary tumor (Peinado et al. 2011). The most well-
documented components of induced pre-metastatic niches are tumor-promoting 
inflammatory cells, although other cell types and the extracellular matrix 
(ECM) may play important roles in different metastatic contexts (Hanahan and 
Weinberg 2011). 
15 
 
 
 
Figure 5. The distinctive microenvironments of tumors 
 
 
 
1.2.2 Multifactorial contributions of tumor-associated stromal cells to the 
hallmarks of cancer 
Most of the hallmarks of cancer are enabled and sustained through 
contributions from different stromal cell types and distinctive subcell types. 
The stromal cells can be divided into three general classes: angiogenic vascular 
cells (AVCs), infiltrating immune cells (IICs), and cancer-associated 
fibroblastic cells (Hanahan et al. 2012) (Figure 6). 
Angiogenic vascular cells 
AVCs consist of endothelial cells and pericytes, that can sustain five of the 
main hallmarks of cancer: the promotion of proliferative signaling, the 
resistance to cell death, the activation of invasion and metastasis, the 
reprogramming of energy metabolism, and the capability of evading immune 
destruction. The neovascularization, involving AVCs, is the best modulator of 
tumor growth, in fact, the “angiogenic switch” increases cancer cell 
proliferation in tumors (Folkman J et al. 1989) as well the inhibition of 
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angiogenesis can impair hyperproliferation, reflecting reduced bioavailability 
of blood-borne mitogenic growth factors. 
 
 
 
Figure 6. Stromal cells sustain the hallmarks of cancer 
 
 
Furthermore, the vascularization allows avoiding cell death that would result 
from hypoxia and lack of serum-derived nutrients and survival factors. The 
proangiogenic factor, vascular endothelial growth factor (VEGF), is 
overespressed in many tumors and leads to the reduction of pericyte coverage 
and the decrease of association between pericytes and endothelium. Thus, 
impairing vascular integrity, it facilitates dissemination of cancer cells from 
primary human tumors. In the same manner, VEGF can facilitate both 
loosening of vessel walls for extravasation, and subsequent induction of 
angiogenesis to support metastatic tumor growth, at distant sites. Inadequate 
vascular function can result in hypoxia, activating the hypoxia inducible 
transcription factor (HIF) response system, that enables cancer cells to survive 
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and proliferate more effectively in conditions of vascular insufficiency 
(Branco-Price C et al. 2012). 
Infiltrating immune cells 
IICs consist of Th2-CD4 T cells, B cells, CD8 T cells, Natural Killer cells, 
tumor-associated macrophages (TAMs), inflammatory monocytes, myeloid-
derived suppressor cells (MDSCs), neutrophils, mast cells, and platelets. IICs 
can sustain seven of the main hallmarks of cancer: the promotion of 
proliferative signaling, the resistance to cell death, the escape of growth 
suppressors, the activation of invasion and metastasis, the induction of 
angiogenesis, the reprogramming of energy metabolism, and the capability of 
evading immune destruction. IICs supply direct and indirect mitogenic growth 
mediators that stimulate proliferation of tumor cells and stromal cells. The 
main released mediators are: epidermal growth factor (EGF), transforming 
growth factor-β (TGF-β), tumor necrosis factor-α (TNF-α), fibroblast growth 
factors (FGFs), various interleukins (ILs), chemokines, histamine, and heparins 
(Balkwill et al. 2005). IICs express and secrete a variety of proteolytic enzymes 
(metallo, serine, and cysteine proteinases and heparanase) that, in addition to 
liberating mitogenic growth factors, can selectively cleave cell-cell and cell-
ECM adhesion molecules, and ECM molecules, thereby disabling growth 
suppressing adhesion complexes maintaining homeostasis (Lu et al. 2011). 
Moreover, another mechanism used by cancer cells to become resistant to cell 
detachment-induced apoptosis that involves IICs, is the binding IICs-cancer 
cells. Thus, IICs can enable cancer cells the ability to survive in ectopic 
microenvironments by suppressing the triggering of cell death pathways. For 
instance, α4-integrin-expressing TAMs promote survival of metastatic breast 
cancer cells in lung by binding vascular cell adhesion molecule-1 (VCAM-1) 
expressed on breast cancer cells (Chen et al. 2011). TAMs also protect breast 
cancer cells from chemotherapy (taxol, etoposide, and doxorubicin)-induced 
cell death by a cathepsin protease-dependent mechanism (Shree et al. 2011). 
Furthermore, IICs have a crucial role in the induction of angiogenesis. In fact, 
while endothelial cells mediate leukocyte recruitment by expressing many 
leukocyte adhesion molecules, IICs produce a diverse assortment of soluble 
factors that influence endothelial cell behavior. The main soluble mediators 
produced by IICs are: VEGF, FGF, TNF-α, TGF-β, platelet-derived growth 
factor (PDGF), chemokines, matrix metalloproteinases (MMPs), proteases, 
DNA-damaging molecules, histamine. All of these effectors have capabilities 
to regulate vascular cell survival, proliferation, and motility, along with tissue 
remodeling, culminating in new vessel formation. In particular, TAMs regulate 
tumor angiogenesis largely through their production of VEGF-A (Lin et al. 
2007), and also mast cells, that are reservoirs of potent vascular mediators 
including VEGF, are important promoter of tumor angiogenesis (Kessler et al. 
1976). Furthermore, neutrophils and their myeloid progenitors, which produce 
MMP-9, are demonstrably involved in angiogenic switching in some tumors 
(Pahler et al. 2008). Platelets release distinctive granules containing either pro- 
or antiangiogenic regulatory molecules, and have been implicated in 
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angiogenesis for decades (Sabrkhany et al. 2011). Moreover, platelets and 
macrophages can be added to the roster of tumor-promoting hematopoietic 
cells that facilitate invasion and metastasis. Interestingly, mast cells and 
macrophages, in primary tumor TMs, provide a wide range of proteases, that 
foster ectopic tissue invasion by remodeling structural components of ECM 
which in turn provide conduits for malignant cell egress, as well as by 
generating ECM fragments with pro-invasive signaling activities (Kessenbrock 
et al. 2010). Furthermore, macrophages are the primary source of EGF, that 
promotes invasion/chemotaxis and intravasation of breast carcinoma cells 
through a paracrine loop operative between tumor cells and macrophages 
(Wyckoff et al. 2004). Finally, functional genetic studies demonstrated that 
also platelets, through platelet-derived TGF-ß ligand, have an invasion- and 
metastasis-promoting activity (Labelle et al. 2011). 
Notably, the most important IICs involved in anti-tumor immunity resistance 
are T regulatory cells. In fact, T regulatory cells typically play an important 
physiological role in suppressing responses to self-antigens, thereby preventing 
autoimmunity. MDSCs, TAMs and mast cells can indirectly foster immune 
suppression through recruitment or promotion of the generation of T regulatory 
cells (Ruffell et al. 2010, Wasiuk et al. 2009). 
Finally, TAMs are implicated in the altered metabolism of tumors, as well as in 
the development of metabolic pathologies (Biswas et al. 2012). 
Cancer-associated fibroblastic cells 
Connective tissue fibroblasts proximal to neoplastic growths can be activated, 
and mesenchymal progenitors—in particular, mesenchymal stem cells (MSCs), 
both local and bone marrow derived—can be recruited and induced to 
differentiate into myofibroblasts defined in part by expression of alpha smooth 
muscle actin (α-SMA) (Paunescu et al. 2011), or into adipocytes defined by 
expression of fatty acid binding protein-4 (FABP4) (Rosen et al. 2006). Each 
of these subtypes can contribute to a variety of tumor-promoting functions, 
with the potential to impact on multiple hallmark capabilities. Thus, for 
example, cancer-associated fibroblastic cells can express and secrete signaling 
proteins that include mitogenic epithelial growth factors—hepatocyte growth 
factor (HGF), EGF family members, insulin-like growth factor-1 (IGF-1), 
stromal cell-derived factor-1 (SDF-1), and a variety of FGFs—with the 
capability to stimulate cancer cell proliferation (Cirri et al. 2011). In addition, 
both activated adipocytes and activated fibroblasts can express many 
mediators, thereby recruiting and activating IICs that, in turn, provide 
mitogenic signals to cancer cells, as well as other cell types in the TM (Dirat et 
al. 2011). Furthermore, cancer-associated fibroblastic cells have also the 
capability to limit the impact on tumor growth and progression of cancer cell 
apoptosis through the secretion of diffusible paracrine survival factors such as 
IGF-1 and IGF-2 (Kalluri et al. 2006) and of ECM molecules and of ECM-
remodeling proteases (Lu et al. 2011). Moreover, cancer-associated adipocytes, 
analogous to IICs, confer a radioresistant phenotype to breast cancer cells 
dependent on adipocyte-derived IL-6 (Bochet et al. 2011). Notably, cancer-
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associated fibroblastic cells, in different TMs, can produce a large amount of 
proangiogenic signaling proteins, including VEGF, FGFs, and IL-8/CXCL8, a 
variety of ECM-degrading enzymes, and they can also produce chemo-
attractants for proangiogenic IICs, thereby indirectly orchestrating tumor 
angiogenesis (Vong et al. 2011). Interestingly, these cells modulate the 
capability of cancer cells to invade locally or establish secondary tumors at 
distant metastatic site through two important hormones, HGF, which stimulates 
c-Met, and TGF-β, that is involved in activating EMT programs in certain 
cancer cells, thereby enabling their capability for invasion and metastasis 
(Chaffer et al. 2011). Another important role of cancer-associated fibroblastic 
cells is the immune destruction resistance through the inhibition cytotoxic T 
cells and NK/T cells, in part by producing TGF- β (Stover et al. 2007). 
Finally, recent data have also revealed a remarkable symbiotic relationship in 
energy metabolism between cancer-associated fibroblastic cells and cancer 
cells. The nature of the symbiosis can evidently vary depending on the TM. In 
some cases, the cancer-associated fibroblastic cells switch on aerobic 
glycolysis, utilizing glucose and secreting lactate that is taken up by cancer 
cells (Balliet et al. 2011). In other cases, the symbiosis is opposite: cancer cells 
switch on aerobic glycolysis, utilizing glucose and exporting lactate, which the 
cancer-associated fibroblastic cells then take up and use as fuel to drive their 
tumor-promoting functional activities (Rattigan et al. 2012) (Figure 7). 
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Figure 7. Multiple stromal cell types and subcell types of the tumor 
microenvironment can variably contribute to, or in some cases oppose, 
acquisition of the hallmarks of cancer 
 
 
 
1.2.3 Cancer-associated fibroblasts (CAFs) 
 In the early growth of tumors, cancer cells form a neoplastic lesion, 
called carcinoma in situ (CIS), that is separated from the surrounding tissue 
and contained within the boundary of a basement membrane. CIS is associated 
with a stroma similar to that observed during wound healing, and it is 
commonly referred to as “reactive stroma”. During cancer progression from 
CIS to invasive carcinoma, the tumor cells invade the reactive stroma. During 
ductal carcinoma in situ (DCIS) the basement membrane, although intact, is 
altered, while during invasive ductal carcinoma it is degraded, thus, enabling 
the direct contact between reactive stroma and cancer cells (Kalluri and 
Zeisberg 2006) (Figure 8). 
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Figure 8. Tumor-stroma interactions during different stages of mammary 
ductal carcinoma progression 
 
 
It is becoming increasingly clear that a subpolulation of fibroblasts, the so-
called cancer-associated fibroblasts (CAFs), are prominent modifiers of cancer 
progression. 
Activation of fibroblasts 
Fibroblasts are non-vascular, non-epithelial and non-inflammatory cells that 
form the basic cellular component of connective tissue and contribute to its 
structural integrity. Tipically, normal fibroblasts (NFs) appear as fusiform 
cells, are embedded within the fibrillar ECM of the connective tissue and 
constitutively express vimentin and fibroblast-specific protein 1 (FSP1). They 
can interact with their surrounding microenvironment through integrins such as 
the α1β1 integrin (Figure 9). In normal conditions, fibroblasts are in an inactive 
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quiescent state with a low proliferation index and minimum metabolic 
capacity. Fibroblasts become activated in wound healing and fibrosis, both 
conditions requiring tissue remodeling. These activated fibroblasts, 
myofibroblasts, were originally described by Giulio Gabbiani in 1971 during 
wound healing in granulation tissues. Myofibroblasts differ morphologically 
and functionally from quiescent fibroblasts. In response to mechanical stress, 
myofibroblasts acquire contractile stress fibers (microfilament bundles), start to 
express α-smooth muscle actin (α-SMA), which is instrumental in the force 
generation, and ED-A splice variant of fibronectin, and form direct cell–cell 
contacts through gap junctions. Once the wound healing process is completed, 
most of the myofibroblasts are removed by apoptosis from the granulation 
tissue (Gabbiani et al. 1971). Active fibroblasts play similar roles in wound 
healing and in cancer, which is considered as a wound that does not heal 
(Svoboda et al. 1986). In fact, during wound healing and in cancers, fibroblasts 
become activated, start to proliferate, secrete higher amounts of ECM 
components, such as type I collagen, tenascin C, EDA-fibronectin and secreted 
protein acidic and rich in cysteine (SPARC). Moreover CAFs, like 
myofibroblasts, are highly heterogeneous, acquire contractile features, and 
express α-smooth-muscle actin (Polyak and Kalluri 2010) (Figure 9). However, 
while in normal wounds active fibroblasts are transient, CAFs are persistent in 
tumors.  
 
 
 
Figure 9. Fibroblast activation 
 
 
Numerous growth factors such as transforming growth factor-β (TGF-β), 
chemokines such as monocyte chemotactic protein 1 (MCP1), and ECM-
degrading proteases have been shown to mediate the activation of fibroblasts 
(Kalluri and Zeisberg 2006). 
In more detail, three alternative models for the evolution of the stromal 
fibroblasts present within invasive human carcinomas are:  
- SELECTION: acquisition of genetic alterations (for instance p53 loss) 
may allow clonal selection of a small population of fibroblasts or 
progenitors that have undergone such alterations, 
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- TRANS-DIFFERENTIATION: populations of normal stromal 
fibroblasts recruited into a tumor may trans-differentiate into CAFs 
without acquiring any genetic alterations, presumably through TM 
interaction (suggesting the possibility that CAFs are essentially 
equivalent to the myofibroblasts present in sites of wound healing and 
chronic inflammation), 
- DIFFERENTIATION: stromal myofibroblasts are recruited from 
specialized circulating progenitor cell types (Orimo and Weinberg 
2006) (Figure 10). 
The main precursors for activated fibroblasts seem to be the local residing 
fibroblasts; they can also originate from pericytes and smooth muscle cells 
from the vasculature or from bone marrow-derived mesenchymal cells. 
Importantly, CAFs can derive from cancer cells (CCs) or endothelial cells, 
respectively via epithelial/endothelial–mesenchymal transition (EMT/EndMT), 
that are biological processes relevant in development, tissue regeneration and 
cancer progression (Räsänen and Vaheri 2010). 
 
 
 
Figure 10. Models for evolution of the stromal fibroblasts in human 
carcinomas 
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CAFs in Breast Cancer (BC) 
According to Orimo and Weinberg (2006), CAFs, present in human invasive 
breast carcinoma, release SDF-1, that is responsible for recruiting endothelial 
progenitor cells (EPCs) into a tumor mass, thereby promoting tumor 
angiogenesis. In addition, SDF-1 secreted from CAFs enhances tumor growth 
by direct paracrine stimulation via the chemokine (C-X-C motif) receptor 4 
(CXCR4) displayed by human breast carcinoma cells, thereby revealing a 
second role for stromal SDF-1 in promoting tumor progression in vivo (Figure 
11). Interestingly, both the tumor-enhancing and myofibroblastic properties of 
CAFs are stably retained by these cells in the absence of ongoing contact with 
breast carcinoma cells. Accordingly, even though the CAFs appear to have 
initially acquired a myofibroblastic phenotype under the influence of 
carcinoma cells, once it is acquired, they display this trait in the absence of 
further signaling from the carcinoma cells (Orimo et al. 2005). 
 
 
 
Figure 11. Stromal SDF-1 enhances tumor growth and tumor angiogenesis 
 
 
In breast tumors, 80% of fibroblasts are in active form. Breast carcinomas can 
activate stromal fibroblasts through secretion of TGF-β. Consequently, CAFs 
enhance tumor growth and angiogenesis via secreted mediators such as VEGF-
A, MMPs, HGF, SDF-1 and TGF-β too. Importantly, SDF-1 and TGF-β 
cytokines maintain the active state of stromal fibroblasts through autocrine 
signaling loops. (Casey et al. 2008, Kojima et al. 2010, Aboussekhra 2011) 
(Figure 12). CAFs have an important role in progression, invasion and 
metastasis of BC (Mao et al. 2012). According to Adams (1988), CAFs 
significantly enhance tumor growth in estrogen receptor (ER)-positive BC 
through the secretion of higher estradiol levels. Moreover, CAFs can promote 
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migration in MDA-MB-231 cells and induce EMT in ER-positive cell lines 
(Hugo et al. 2012). Notably, the inactivation of phosphatase and tensin 
homolog (PTEN) in CAFs allows BC onset and invasion (Trimboli et al. 2009). 
Furthermore, it has been shown that CAFs promote breast cancer metastasis 
through chemokine (C-C motif) ligand 2 (CCL2) secretion (Tsuyada et al. 
2012). Recently, it has been shown that Snail1-expressing fibroblasts in the 
tumor microenvironment display mechanical properties that support metastasis 
(Stanisavljevic et al. 2015). Finally, breast CAFs have also an important role in 
therapy resistance. According to Mao et al. (2015), CAFs induce trastuzumab 
resistance in HER2 positive breast cancer cells. 
 
 
 
Figure 12. Breast carcinoma-mediated activation of fibroblasts 
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1.3 Exosomes 
 
 
 
1.3.1 Biogenesis and secretion of exosomes 
Exosomes were first observed in 1983 in differentiating reticulocytes. It 
was shown that during reticulocyte maturation, the transferrin receptor and 
many membrane-associated proteins were shed in small membrane vesicles via 
an unknown secretory process (Harding et al. 1983). Only in 1987, the word 
“exosome” was proposed for these extracellular vesicles (EVs) of endosomal 
origin (Johnstone et al. 1987). Firstly, this process was considered as a way for 
cells to eliminate unwanted proteins and molecules. However, in recent years, 
exosomes have emerged as important mediators of cellular communication that 
are involved in both normal physiological processes, such as lactation, immune 
response and neuronal function, and also in the development and progression 
of diseases, such as liver disease, neurodegenerative diseases and cancer. 
Exosomes have been identified in most bodily fluids, including urine, amniotic 
fluid, serum, saliva, breast-milk, cerebrospinal fluid, and nasal secretions. 
Importantly, cancer cells have been shown to secrete exosomes in greater 
amounts than normal cells, indicating their potential use as biomarkers for 
diagnosis of disease (Hannafon and Ding 2013). 
Exosomes have a diameter of 30-100 nm, and are generally discriminated by 
size from other EVs: microvesicles, also called ectosomes, (with a diameter of 
100–1000 nm), and apoptotic bodies (>1 µm in diameter) (Mittelbrunn and 
Sánchez-Madrid 2012). Exosomes are formed as intra-luminal vesicles (ILVs) 
by budding into early endosomes and multi-vesicular bodies (MVBs). In 
particular, the main mechanisms involved in the biogenesis of ILVs are: the 
endosomal-sorting complex required for transport (ESCRT) machinery and 
ESCRT-indipendent mechanisms. ESCRT consists of four complexes plus 
associated proteins: ESCRT-0 is responsible for cargo clustering in a ubiquitin-
dependent manner, ESCRT-I and ESCRT-II induce bud formation, ESCRT-III 
drives vesicle scission, and the accessory proteins allow dissociation and 
recycling of the ESCRT machinery. The main members of the ESCRT family 
are TSG101 and ALIX (Baietti et al. 2012). Recent studies have shown that 
also ESCRT-indipendent mechanisms are involved in ILV formation: these 
mechanisms involve lipids, tetraspanins, or heat shock proteins. Of note, 
mammalian cells depleted for key ESCRT components still form MVBs. 
Exosome biogenesis can be mediated by lipids such as ceramide, cholesterol, 
phosphatidic acid (Trajkovic et al. 2008, Ghossoub et al. 2014). On the other 
hand, four-transmembrane domain proteins of the tetraspanin family (for 
instance CD63, CD81) have recently been proposed as instrumental in 
selecting cargoes for exosome secretion (van Niel et al. 2011, Perez-Hernandez 
et al. 2013). Finally, recent studies have shown that the chaperone HSC70 
allows the selective transfer of cytosolic proteins containing a KFERQ-motif to 
ILVs (Sahu et al. 2011). It is still unknown whether these mechanisms act 
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simultaneously on the same MVB or on different MVBs. The fate of MVBs 
can be either fusion with lysosomes or fusion with the plasma membrane, 
which allows the release of their content to the extracellular milieu. Several 
RAB proteins (RAB11, RAB27 and RAB35) have been shown to be involved 
in the transport of MVBs to the plasma membrane and in exosome secretion 
(Stenmark 2009, Savina et al. 2005, Hsu et al. 2010). Interestingly, the 
involvement of RAB27A in vesicle secretion was confirmed in numerous 
tumor cell lines: murine melanoma (Peinado et al. 2012) and mammary 
carcinoma (Bobrie et al. 2012). The last and least characterized step of 
exosome biogenesis consists of the fusion of the MVBs with the plasma 
membrane, with consequent release of the EVs into the extracellular space. The 
soluble NSF-attachment protein receptor (SNARE) complex has been 
implicated in this process, and the Ca2+-regulated vesicle-associated 
membrane protein 7 (VAMP7), a member of the SNARE complex, appears to 
be necessary for MVB fusion with the plasma membrane in leukemic cells, but 
not in MDCK cells (Fader et al. 2009, Proux-Gillardeaux et al. 2007, Kowal et 
al. 2014) (Figure 13). 
Once secreted, exosomes can bind to cells through receptor–ligand 
interactions, similar to cell–cell communication mediating, for example, 
antigen presentation. Alternatively, exosomes could putatively attach or fuse 
with the target-cell membrane, delivering exosomal surface proteins and 
perhaps cytoplasm to the recipient cell. Finally, exosomes may also be 
internalized by the recipient cells by mechanisms such as endocytosis (Valadi 
et al. 2007). 
 
 
 
Figure 13. Exosome biogenesis and secretion 
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1.3.2 Exosome composition 
 Over the years, it has been recognized that not only the contents inside 
the exosomes but also the components in exosome structure can influence 
distant cell signaling. Primarily, exosomes carry proteins: membrane transport 
proteins and fusion proteins, such as RAB GTPases, annexins, flotillins, and 
MVB biogenesis proteins, such as Alix and tumor susceptibility gene Tsg101. 
Additionally, the protein families that are associated with lipid micro-domains, 
such as integrins and tetraspanins, such as CD9, CD81, CD82, CD83, and 
CD63 are also important part of exosome. The pool of exosome proteins are 
both conserved and also cell type specific, depending on the cells from where 
exosomes are secreted. Heat shock proteins (Hsp), CD63 and tetraspanins are 
the most prominent evolutionary conserved proteins in exosomes. Cytoskeleton 
and metabolism-related proteins form the pool of other frequently found 
proteins that include β-actin, tubulins, myosin, cofilin, glyceraldehyde 3-
phosphate dehydrogenase, and major histocompatibility complex (MHC) 
classes I and II molecules. The lipid content of exosomes can be categorized 
into two types either conserved or matching the characteristics of the cell from 
where they are originating. These structural lipids do not only give shape to 
exosomes, but have also shown to take part in cell communication. Exosomes 
are enriched in lipids that are associated with lipid rafts: sphingolipids, 
cholesterol, glycerophospholipids, and ceramide that have characteristic 
elongated saturated fatty-acyl chains. Exosomal signaling mediators include 
prostaglandins, arachidonic acid, phospholipase A2, phospholipases C and D 
(Azmi et al. 2013). In 2007, Valadi and colleagues have elucidated that 
exosomes contain also mRNA and microRNAs. Recently, Sato-Kuwabara and 
colleagues (2015) have demonstrated that exosomes contain also non-coding 
RNAs and Melo and colleagues (2014) have shown that breast cancer 
associated exosomes contain miRs associated with RNA-induced silencing 
complex(RISC)-laoding complex, thus displaying cell-indipendent capacity to 
process precursor microRNAs (Figure 14). 
 
 
 
Figure 14. Exosome composition 
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1.3.3 The sorting mechanisms and the function of exosomal miRs 
 Recently, mRNAs and microRNAs have been identified in exosomes, 
which can be taken up by neighboring or distant cells and subsequently 
modulate recipient cells. microRNAs are a class of 17–24 nucleotides small, 
non coding RNAs, which mediate post-transcriptional gene silencing by 
binding to the 3’-untranslated region or open reading frame region of target 
mRNAs. miRs are involved in many biological activities such as cell 
proliferation, cell differentiation, cell migration, disease initiation, and disease 
progression. Their dysregulation plays an essential role in the development and 
progression of cancer: miRs are up- or down-regulated in malignant tissues 
compared to the normal counterpart, thereby they can be considered as 
oncogenes or tumor-suppressors, respectively. Accumulating evidence has 
shown that miRs can stably exist in body fluids, including saliva, urine, breast 
milk, and blood. In addition to being packed into exosomes or microvesicles, 
extracellular miRs can be loaded into high-density lipoprotein, or bound by 
AGO2 protein outside of vesicles (Garofalo et al. 2014). All these three modes 
of action protect miRs from degradation and guarantee their stability. 
There are four potential modes for sorting of miRs into exosomes, although the 
underlying mechanisms remain largely unclear. These include:  
- the neural sphingomyelinase 2 (nSMase2)-dependent pathway (Kosaka et al. 
2013),  
- the miR motif and sumoylated heterogeneous nuclear ribonucleoproteins 
(hnRNPs)-dependent pathway (the GGAG motif in the 3’ portion of miR 
sequences causes specific miRs to be packed into exosomes) (Villarroya-Beltri 
et al. 2013), 
- the 3’-end (uridylated or adenylated) of the miR sequence-dependent pathway 
(Koppers-Lalic et al. 2014),  
- the miR induced silencing complex (miRISC)-related pathway (AGO2 could 
act in exosomal miR sorting) (Melo et al. 2014). 
In summary, specific sequences present in certain miRs may guide their 
incorporation into exosomes, whereas some enzymes or other proteins may 
control sorting of exosomal miRs as well in a miR sequence-independent 
fashion. 
According to Goldie and colleagues (2014), among small RNAs, the proportion 
of miRs is higher in exosomes than in their parent cells. As some profiling 
studies have shown, miRs are not randomly incorporated into exosomes. 
Guduric-Fuchs and colleagues (2012) have analyzed miR expression levels in a 
variety of cell lines and their respective derived exosomes, and have found that 
a subset of miRs (miR-150, miR-142-3p, and miR-451) preferentially entered 
exosomes. Similarly, Ohshima and colleagues (2010) have found that members 
of the let-7 miR family were abundant in exosomes derived from gastric cancer 
cell lines, but were less abundant in exosomes derived from other cancer cells. 
Moreover, some reports have shown that exosomal miR expression levels are 
altered under different physiological conditions. The level of miR-21 was 
lower in exosomes from the serum of healthy donors than those glioblastoma 
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patients (Skog et al. 2008). Levels of let-7f, miR-20b, and miR-30e-3p were 
lower in vesicles from the plasma of non small-cell lung carcinoma patients 
than normal controls (Silva et al. 2011). All these studies show that parent cells 
possess a sorting mechanism that guides specific intracellular miRs to enter 
exosomes. 
The miRs in cell-released exosomes can circulate with the associated vehicles 
to reach neighboring cells and distant cells. After being delivered into acceptor 
cells, exosomal miRs play functional roles. The functions of exosomal miRs 
can be generally classified into two types. One is the conventional function: the 
negative regulation of target genes. For example, exosomal miR-105 released 
from breast cancer cell lines reduced ZO-1 gene expression in endothelial cells 
and promoted metastases to the lung and brain (Zhou et al. 2014). Another 
example is the exosomal miR-92a, derived from leukemia cells. miR-92a 
significantly reduced the expression of integrin α5 in endothelial cells and 
enhanced endothelial cell migration and tube formation (Umezu et al. 2012). 
The other function is a novel mechanism that has been identified in some miRs 
such as exosomal miR-21 and miR-29a, that in addition to the classic role of 
targeting mRNAs, were first discovered to have the capacity to act as ligands 
that bind to toll-like receptors (TLRs) and activate immune cells (Fabbri et al. 
2012). In summary, the transfer of exosomal miRs is a new mechanism of 
intercellular communication that can initiate and promote tumor progression. 
Finally, the amount and composition of exosomal miRs released in biologic 
fluid, such as urine and blood, can differ between patients with disease and 
healthy individuals. Thus, exosomal miRs have a potential role as noninvasive 
biomarkers to indicate disease states (Lin et al. 2015). 
 
 
 
1.3.4 Exosomes in cancer development and metastasis 
 Over the last decade, a number of studies have revealed that exosomes 
influence major tumor-related pathways, such as hypoxia-driven epithelial-to 
mesenchymal transition, cancer stemness, angiogenesis, and metastasis (Azmi 
et al. 2013) (Figure 15). Grange and colleagues (2011) have shown that 
exosomes released from human renal cancer stem cells stimulated angiogenesis 
and formation of lung pre-metastatic niche. A number of studies have indicated 
that hypoxia promotes exosome secretion in different tumor types. In a breast 
model, King and colleagues (2012) showed that hypoxia-mediated activation of 
HIF-1α enhanced the release of exosomes and resulted in aggressive cell 
phenotype. While in a kidney tumor model, Borges and colleagues (2013) 
showed that TGF-β1-containing (a promoter of EMT) exosomes from injured 
epithelial cells activated fibroblasts to initiate tissue regenerative response and 
fibrosis. In 2012, Peinado and colleagues have demonstrated that exosomes 
from highly metastatic melanomas increased the metastatic behavior of 
primary tumors by permanently ‘educating’ bone marrow progenitors through 
the receptor tyrosine kinase MET. Moreover, Luga and colleagues (2012) have 
31 
 
shown that fibroblast-derived exosomes promoted breast cancer cell protrusive 
activity and motility via Wnt-planar cell polarity signaling. Interestingly, tumor 
derived exosomes can reprogram fibroblasts to CAFs through TGF-β, thereby 
enhancing tumor progression (Webber et al. 2015). Recently, Khokha’s group 
has demonstrated that cancer cell motility was induced by exosomes released 
from CAFs silenced for tissue inhibitor of metalloproteinases (TIMP). In this 
system, TIMP knock down resulted in increased expression of the 
metalloproteinase ADAM10 in the exosomes (Shimoda et al. 2014).  
Notably, exosomes regulate also immune response. For instance, Zhang and 
colleagues (2006) have demonstrated that membrane form of TNF-alpha 
secreted in exosomes prevented cytotoxic T cell activation induced cell death. 
Finally, exosomes have an important role in therapy resistance too. Khan and 
colleagues (2009) have shown that exosomal secretion of survivin suppressed 
the efficacy of proton irradiation in a cellular model. In another study, Safaei 
and colleagues (2005) have shown that exosomes mediated cisplatin resistance 
in ovarian cancer. More recently, Ciravolo and collegues (2012) have 
elucidated a potential role of HER-2-overexpressing exosomes in trastuzumab 
resistance.  
 
 
 
Figure 15. Role of exosomes in cancer progression 
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2. AIM OF THE STUDY 
 
Despite many novel therapeutic approaches, breast cancer remains one 
of the leading cause of cancer mortality among women. Recent findings 
indicate that cancer-associated fibroblasts (CAFs), the major components of the 
tumor microenvironment (TM), play a crucial role in breast cancer progression, 
but how they promote tumorigenesis is poorly understood. Increasing evidence 
indicates that exosomes and their cargo, including microRNAs (miRs), may 
vehicolate between cells and affect the biological behavior of recipient cells. 
Therefore, one alternative mechanism of the promotion of breast cancer 
progression by CAFs may be through CAF-secreted exosomes, which would 
deliver oncogenic miRs (oncomiRs) to breast cancer cells. Thus, the aim of this 
study is to analyze the tumor-stroma interactions mediated by exosomes within 
the TM. In particular, we aim to identify the oncomiRs up-regulated in CAF 
exosomes that could have a significant role in breast cancer. Finally, we intend 
to clarify the mechanisms underlying protumorigenic actions of CAF exosomes 
and exosomal miRs in breast cancer. 
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3. MATERIALS AND METHODS 
 
3.1 Primary and continuous cells and mammosphere cultures 
Breast cancer cell line T47D, from ATCC, was grown in RPMI-1640. 
Primary cultures of fibroblasts, from “Clinica Mediterranea” (NA), were grown 
in Dulbecco’s Modified Eagle’s Medium/Nutrient F12-Ham (DMEM-F12). 
Media were supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
and 100 U/ml penicillin/streptomycin. All media and supplements were from 
Sigma-Aldrich (Milan, Italy). 
For mammosphere cultures, single cell suspensions were plated at a density of 
1,000 cells/ml in Corning ultra-low attachment multiwell plates. Cells were 
grown in stem medium: a serum-free DMEM-F12 (Sigma, Milan, Italy), 
supplemented with B27 (Life technologies, Milan, Italy), 10 ng/ml EGF 
(Sigma, Milan, Italy) and 20 ng/ml bFGF (BD Biosciences, Milan, Italy) and 
1X antibiotic-antimycotics (Life technologies, Milan, Italy). After 4-7 days, 
mammospheres appeared as spheres of floating viable cells. 
 
 
 
3.2 Isolation of primary cell cultures from human breast biopsies 
Human breast biopsies (samples from “Clinica Mediterranea”, NA) 
were cut by mechanical fragmentation with sterile scissors and tongs. Then, the 
tissue extracellular matrix was digested through enzymatic digestion (treatment 
with collagenase (Sigma-Aldrich), overnight, in continuous agitation, at 37°C). 
The drawn cellular suspensions were separated on the basis of their weights by 
two different centrifugations: the first one at 500 rpm for 5 minutes to obtain 
epithelial cell pellets, the second one at 1200 rpm 5 minutes to obtain fibroblast 
pellets. 
 
 
 
3.3 Immunocytochemistry 
The separation between epithelial cells and fibroblasts from human 
breast biopsies was confirmed by using the cell block technique (Shandon 
cytoblock kit) followed by immunocytochemistry, in collaboration with 
Professor Terracciano. A primary antibody was used for CK22 (pan-keratin), a 
known epithelial marker, in order to discriminate epithelial cells from 
fibroblasts. 
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3.4 Exosome isolation 
Exosomes were isolated from cell culture media of primary fibroblasts 
that were grown in DMEM-F12 (Sigma-Aldrich), supplemented with 10% 
Exo-FBS (FBS depleted of exosomes, SBI, System Biosciences) and 1X 
antibiotic-antimycotics (Life technologies, Milan, Italy). The appropriate 
culture media were centrifuged at 3000 g 15 minutes at 4°C or RT to remove 
cellular debris. The supernatants were transferred into sterile tubes and an 
appropriate volume of the ExoQuick-TCTM Exosome Isolation Reagent (SBI, 
System Biosciences) was added, considering 2 ml of ExoQuick-TCTM solution 
every 10 ml of cell culture medium. Then, the tubes were subjected to mild 
agitation until the separation between the two phases was no longer visible. 
Finally, the tubes were kept at 4°C O/N (12 hours at least were necessary). The 
following day the solutions with the ExoQuickTM Reagent and cell media were 
centrifuged firstly at 1500 g for 30 minutes, and then at 1500 g for 5 minutes, 
both centrifugations at 4°C or RT. At the end of the steps, white/beige 
exosomal pellets appeared. 
 
 
 
3.5 Cell transfection  
For miR transient overexpression/downregulation, cells at 50% 
confluence were transfected using Oligofectamine (Invitrogen, Milan, Italy) 
and 100nM of pre-miR-21, pre-miR-143-3p, pre-miR-378e, scrambled pre-
miR, or 200nM of anti-miR-21, anti-miR-143-3p, anti-miR-378e, scrambled 
anti-miR (Ambion®, Life Technologies). 
Transfection of CAFs with Cy3-labeled-miRs  
CAFs were transfected with 10nM of Cy3-labeled-miRs (miR-21-5p, miR-143-
3p, miR-378e, Tebu-bio, San Diego, CA) using Oligofectamine (Invitrogen, 
Milan, Italy). Six hours after transfection, cells were washed two times with 
PBS, and the culture media were switched to fresh DMEM-F12 1% A/A, 10% 
exo-FBS. After incubation for a day, the culture media were collected and used 
for exosome preparation. 
 
 
 
3.6 RNA extraction and Real Time PCR 
Total RNAs (microRNAs and mRNAs) were extracted using Trizol 
(Invitrogen, Milan, Italy) according to the manufacturer’s protocol. Reverse 
transcription of total RNA was performed starting from equal amounts of total 
RNA/sample (150/500ng) using miScript reverse Transcription Kit (Qiagen, 
Milan, Italy) for miR analysis, and using SuperScript® III Reverse 
Transcriptase (Invitrogen, Milan, Italy) for mRNA analysis. Quantitative 
analysis of miR-21, miR-143, miR-378e and RNU6A (as an internal reference) 
was performed by Real Time PCR using specific primers (Qiagen, Milan, 
Italy) and miScript SYBR Green PCR Kit (Qiagen, Milan, Italy). Real Time 
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PCR was also used to assess the mRNAs of NANOG, OCT3/4, SOX2, SNAIL 
and β-ACTIN (as an internal reference), using iQTM SYBR Green Supermix 
(Bio-Rad, Milan, Italy). The primer sequences were:  
NANOG-FW: 5’-CAAAGGCAAACAACCCACTT-3', 
NANOG-RV: 5’-TCTGGAACCAGGTCTTCACC-3', 
OCT3/4-FW: 5’-CGAAAGAGAAAGCGAACCAG-3’, 
OCT3/4-RV: 5’-GCCGGTTACAGAACCACACT-3’, 
SOX2-FW: 5’-GCACATGAACGGCTGGAGCAACG-3’, 
SOX2-RV: 5’-TGCTGCGAGTAGGACATGCTGTAGG-3’, 
SNAIL-FW: 5’-AGTGGTTCTTCTGCGCTACT-3’, 
SNAIL-RV: 5’-GGGCTGCTGGAAGGTAAACT-3’, 
ACTIN-FW: 5’-TGCGTGACATTAAGGAGAAG-3’,  
ACTIN-RV: 5’-GCTCGTAGCTCTTCTCCA-3’.  
The reaction for detection of mRNAs was performed in this manner: 95 °C for 
5’, 40 cycles of 95 °C for 30’’, 62 °C for 30’’ and 72 °C for 30’’. The reaction 
for detection of miRs was performed in this manner: 95 °C for 15’, 40 cycles 
of 94 °C for 15’’, 55 °C for 30’’ and 70 °C for 30’’. All reactions were run in 
triplicate. The threshold cycle (CT) is defined as the fractional cycle number at 
which the fluorescence passes the fixed threshold. For relative quantization, the 
2(-∆∆CT) method was used. Experiments were carried out in triplicate for each 
data point, and data analysis was performed by using Applied Biosystems 
StepOnePlus™ Real-Time PCR Systems. 
 
 
 
3.7 NCounter miRNA assay 
Exosomes were isolated from four different samples of primary 
fibroblasts: two normal and two cancer-associated fibroblasts. Then, exosomal 
RNA was extracted in order to perform an “nCounter miRNA assay” 
(nanoString Technologies, OSU, Columbus, OHIO). Eight-hundred human 
miRs were digitally detected and counted in a singol reaction without 
amplification. System performance consisted of 6 positive miRNA assay 
controls, 6 negative miRNA assay controls, and 5 mRNA housekeeping 
controls. 100ng of purified total RNA was used as starting material. miR 
expression levels were measured calculating the ratio of geom. means (Normal 
fibroblast exosomes vs CAF exosomes). 
 
 
 
3.8 Protein isolation and Western blotting 
Cells were washed twice in ice-cold PBS, and lysed in JS buffer (50mM 
HEPES ph 7.5 containing 150mM NaCl, 1% Glycerol, 1% Triton X100, 
1.5mM MgCl2, 5mM EGTA, 1mM Na3VO4, and 1X protease inhibitor 
cocktail). Exosomes were lysed in RIPA lysis buffer (Sigma-Aldrich) 
containing protease and phosphatase inhibitors (Roche Diagnostics GmbH, 
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Mannheim, Germany). Protein concentration was determined by the Bradford 
assay (Bio-Rad, Milan, Italy) using bovine serum albumin (BSA) as the 
standard, and equal amounts of proteins were analysed by SDS-PAGE (12% or 
15% acrylamide). Gels were electroblotted onto nitrocellulose membranes (GE 
Healthcare, Milan, Italy). For immunoblot experiments, membranes were 
blocked for 1 hour with 5% non-fat dry milk in Tris Buffered Saline (TBS) 
containing 0,1% Tween-20, and incubated at 4°C overnight with primary 
antibodies. Detection was performed by peroxidase-conjugated secondary 
antibodies using the enhanced chemiluminescence system (Thermo, Euroclone, 
Milan, Italy). Primary antibodies used were: anti-β-actin and anti-α-tubulin 
from Sigma-Aldrich (Milan, Italy), anti-α-SMA, anti-E-cadherin, anti-ZEB, 
anti-OCT3/4, anti-NANOG, anti-SNAIL, anti-CD63, anti-hsp70, anti-ALIX, 
anti-TSG101 from Santa Cruz Biotechnology (CA, USA). 
 
 
 
3.9 Immunoflurescence analysis 
Uptake of fibroblast exosomes by T47D cells  
Once isolated, exosomes were labeled with PKH26, a red fluorescent cell 
membrane linker (Sigma-Aldrich). For immunofluorescence, cells grown on 
glass coverslips were treated at different incubation times with PKH26-
exosomes, washed six times with PBS and fixed with 4% paraformaldehyde in 
PBS for 20 minutes at room temperature. The coverslips were washed three 
times in PBS. Then, cells were permeabilized with PBS 0.5% Triton X-100 for 
15 minutes at room temperature, and blocked in PBS 1% bovine serum 
albumin (BSA) for 15 minutes. Cells were incubated with anti-tubulin antibody 
(Santa Cruz), diluted in PBS 1% BSA, for 1 hour at 37°C. Coverslips were 
washed 3 times with PBS and treated with Alexa Fluor 488 Goat Anti-Mouse 
IgG (Invitrogen) for 30 minutes at 37°C. Coverslips were washed and mounted 
with Gold antifade reagent with DAPI (Invitrogen). The cells were visualized 
by confocal microscopy. 
Shuttling assays for fluorescently-labeled miRNAs 
After a day from the transfection of CAFs with Cy3-labeled-miRs, exosomes 
were isolated from cell media, and T47D cells grown on glass coverslips were 
treated for 24 hours with the isolated exosomes. For immunofluorescence, it 
was used the same protocol as above, but cells were incubated with anti-CD63 
primary antibody (Santa Cruz), then with Alexa Fluor 488 Goat Anti-Rabbit 
IgG (Invitrogen). 
 
 
 
3.10 TGF-β treatment  
TGF-β2 human recombinant (SRP3170-5UG, Sigma-Aldrich) was used 
at a final concentration of 10ng/ml for 48 hours. It was added every 24 hours to 
fibroblast primary cultures grown in DMEM-F12 1% A/A, 10% exo-FBS. 
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3.11 Mammosphere formation assay 
T47D cells were suspended 1000 cells/well in 1 ml of stem medium and 
plated into ultra-low attachment 48-well plates in presence of normal fibroblast 
or CAF exosomes. Alternatively, T47D cells were transfected with miRs or 
anti-miRs for 48 hours or 24 hours, respectively. Then, 1000 cells/well were 
suspended in 1 ml of stem medium and plated into ultra-low attachment 48-
well plates.  After 4-7 days, the formed mammospheres were counted, and the 
diameters were measured. 
 
 
 
3.12 Statistical analysis 
All experiments were repeated at least three times. Continuous variables 
are given as mean ± standard deviation. For comparisons between two groups, 
the Student’s t test was used to determine differences between mean values for 
normally distributed. Comparisons among more than three groups were 
determined by one-way ANOVA followed by Bonferroni’s post hoc testing. 
All data were analyzed for significance using GraphPad Prism 6 software (San 
Diego, CA, USA). P values less than 0.05 were considered significant.  
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4. RESULTS 
 
4.1 Isolation and characterization of primary fibroblasts from human 
breast biopsies 
Derivate primary cultures of breast fibroblasts is an important starting 
point for studying the interactions between the microenvironment and breast 
cancer. In order to obtain primary fibroblast cultures, we cut human breast 
biopsies by mechanical fragmentation with sterile scissors and pliers. Then, we 
subjected the tissue extracellular matrix to enzymatic digestion. The next day, 
we separated the drawn cellular suspensions on the basis of their weights by 
two different centrifugations: with the first centrifugation (500 rpm 5’) we 
obtained pellets of epithelial cells, then, with the centrifugation of the obtained 
supernatants (1200 rpm 5’) we isolated fibroblasts. The correct separation of 
these two different cell populations was confirmed by using the cell block 
technique (Shandon cytoblock kit) followed by immunocytochemistry for 
CK22 (pan-keratin), a known epithelial marker (in collaboration with Professor 
Terracciano’s lab) (Figure 16a). Moreover, we verified that fibroblast cultures 
were negative for E-cadherin by western blot analysis. Since α-SMA is a 
known CAF marker, we evaluated whether this protein was overespressed in 
CAFs respect to normal fibroblasts by western blot analysis. As expected, 
fibroblasts were negative for E-cadherin (Figure 16b) and CAFs overexpressed 
the protein α-SMA as compared to normal fibroblasts (NFs) (Figure 16c). 
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Figure 16. Characterization of human breast fibroblasts. The correct separation 
of cell populations of the patient #3 biopsy was confirmed: fibroblasts were 
CK22 negative (CK22-), whereas epithelial cells resulted CK22 positive 
(CK22+) (a). Cancer-associated fibroblasts (CAFs), patients #3 and #4, 
overexpressed α-SMA as compared to normal fibroblasts (NFs), patients #1 
and #2 (c). All the fibroblasts were E-cadherin (E-cad) negative as compared to 
the positive control, T47D cells (b). Actin (b) and α-tubulin (c) were used as 
loading controls. 
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4.2 Identification of exosomal proteins in breast fibroblast exosomes 
To characterize breast fibroblast exosomes, isolated with ExoQuick-
TCTM solution, we performed a western blot analysis for different types of 
exosomal proteins: the tetraspanin CD63, the heat shock protein Hsp70 and the 
endosomal proteins, Alix and Tsg101. As shown in Figure 17, we confirmed 
that these exosomal markers were expressed both in normal fibroblast 
exosomes (patients #5, #6 and #10) and in CAF exosomes (patients #7, #9 and 
#11). 
 
 
 
Figure 17. Exosomal markers. Exosomal proteins (Hsp70, Alix, CD63, 
Tsg101) were expressed in breast fibroblast exosomes, both in normal 
fibroblast exosomes (NF ex) and in CAF exosomes (CAF ex). 
 
 
 
4.3 Identification of oncogenic miRs in CAF exosomes 
To identify oncogenic miRs in CAF exosomes, we set up a genome-
wide expression profiling of miRs (nCounter miRNA assay, nanoString 
Technologies, OSU) comparing exosomal miRs derived from two breast CAFs 
(patients #3 and #4) and two normal fibroblasts (patients #1 and #2). We found 
that three miRs were significantly up-regulated in CAF exosomes respect to 
normal fibroblast exosomes: miR-21-5p, miR-378e, and miR-143-3p (Table 1). 
Then, we validated the array data by Real Time PCR. As shown in Figure 18, 
we confirmed that these miRs were up-regulated in CAF exosomes respect to 
NF exosomes. Notably, we found an up-regulation of miR-143-3p also in CAF 
cells as compared to NF cells, but we did not observe the same for both miR-
21-5p and miR-378e (Figure 18). 
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 Ratio of geom means: 
NF exosomes 
vs 
CAF exosomes 
 
Unique id 
1 0,537960845 hsa-miR-21-5p 
2 0,703937608 hsa-miR-378e 
3 0,768350227 hsa-miR-143-3p 
4 0,795360008 hsa-miR-1246 
5 0,813311489 hsa-miR-1253 
6 0,880781514 hsa-miR-155-5p 
7 0,938786077 hsa-miR-549 
8 1,032793771 hsa-miR-125b-5p 
9 1,228928787 hsa-miR-1283 
10 1,256584027 hsa-miR-25-3p 
11 1,294286206 hsa-miR-302d-3p 
 
Table 1. miRNA expression profiles in NF exosomes vs CAF exosomes. Three 
miRs were significantly up-regulated in CAF exosomes as compared to NF 
exosomes. 
 
 
 
Figure 18. Array validation. Real Time PCR of miR-21, miR-378e, and miR-
143 expression levels in fibroblast exosomes and cells. 
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4.4 TGF-β increases miR-21, miR-143, and miR-378e levels in normal 
fibroblast exosomes 
We wondered whether TGF-β, in addition to its direct role in the 
activation of normal fibroblasts to CAFs, could play a role in the 
overexpression of these miRs. To this aim, we treated two normal fibroblasts 
(patients #2 and #5) with TGF-β at the final concentration of 10ng/mL for 48 
hours. Then, we performed a Real Time PCR to evaluate the exosomal levels 
of miR-21, miR-143 and miR-378e. We found that exosomes isolated from 
TGF-β-treated-fibroblasts exhibited increased levels of these miRs as 
compared to exosomes isolated from non treated-fibroblasts (Figure 19). 
 
 
 
Figure 19. TGF-β increases miR-21, miR-143, and miR-378e levels in normal 
fibroblast exosomes. Real Time PCR of miR-21, miR-378e, and miR-143 
expression levels in exosomes isolated from normal fibroblasts (patients #2 and 
#5) treated or not with TGF-β (10ng/mL). 
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4.5 Breast fibroblast-derived exosomes are transferred to T47D cells 
To examine whether fibroblast exosomes could be transferred to breast 
cancer cells (T47D), we isolated exosomes from both normal and cancer-
associated fibroblast conditioned media and we fluorescently labeled them with 
PKH26. Then, we cultured T47D cells with PKH26 fluorescently labeled 
exosomes for different times (30 minutes and 24 hours). Then, we stained the 
treated T47D cells using blue DAPI (nuclei) and green ALEXA488-conjugated 
anti-tubulin antibody. As shown in Figure 20, we confirmed the ability of 
T47D cells to uptake NF- (patients #2 and #6) and CAF- (patient #3) exosomes 
using a confocal microscopy. Notably, as shown in Figure 20b, we observed 
the best uptake after 24 hours of exosome treatment. To get further evidence 
for exosome uptake, we collected a z-stack of six images (Figure 21). NF 
exosomes (patient #6, Figure 21a) and CAF exosomes (patient #3, Figure21b) 
were clearly uptaken from T47D cells after 24 hours of treatment, as 
demonstrated by the co-localization of ALEXA488 and PKH26 signals. These 
results indicate that NF- and CAF- derived exosomes can be transferred into 
T47D cells, suggestive of a potential role in regulating breast cancer biology. 
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Figure 20. Breast fibroblast-derived exosomes are transferred to T47D cells. 
T47D cells were cultured in absence (control) or in presence of NF- (patients 
#2 and #6) or CAF- (patient #3) derived PKH26-labeled exosomes for 30 
minutes (a) or 24 hours (b). Exosomes were uptaken from T47D cells, as 
shown using a confocal microscope (original magnification, ×60). T47D cells 
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were stained using DAPI (nuclei) and ALEXA488-conjugated anti-tubulin 
antibody. Scale bar: 10µm. 
 
 
 
Figure 21. Z stack images of exosome uptake. T47D cells were cultured in 
presence of fibroblast PKH26-labeled exosomes for 24 hours. T47D cells were 
stained using DAPI (nuclei) and ALEXA488-conjugated anti-tubulin antibody. 
Six images for each point were acquired, and slice thickness was 1µm. NF 
exosomes (patient #6, a) and CAF exosomes (patient #3, b) were uptaken from 
T47D cells, as demonstrated by the co-localization of ALEXA488 and PKH26 
signals. Confocal microscope (original magnification, ×60). Scale bar: 10µm. 
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4.6 miRs released by CAFs are shuttled into breast cancer cells via 
exosomes 
In order to demonstrate that CAFs could transfer via exosomes miR-21, 
miR-143 and miR-378e in T47D cells, we treated T47D cells with CAF- or 
NF- isolated exosomes (CAF patients #3, #7 and #8, NF patient #6) for 24 
hours. Then, we performed a Real Time PCR to evaluate miR levels in T47D 
cells. As shown in Figure 22a, T47D cells treated with CAF exosomes 
exhibited increased levels of these miRs as compared to both non treated T47D 
cells and T47D cells treated with NF exosomes. In addition, to visualize the 
transport of extracellular miRs derived from CAFs into T47D cells, we 
transfected CAFs (patient #11) with cy3-labeled miRs (cy3-miR-21-5p, cy3-
miR-143-3p, cy3-miR-378e). The next day, we isolated exosomes from CAF 
cell media and we cultured T47D cells with them. Twenty-four hours after the 
treatment, we stained the treated cells using blue DAPI (nuclei) and green 
ALEXA488-conjugated anti-CD63 antibody. As shown in Figure 22b, we 
detected the signals of cy3-miRs in the cytoplasm of T47D cells, using a 
confocal microscopy. Notably, as shown in z-stack images (Figure 23), cy3-
miRs co-localized with the signals of an exosomal marker, CD63. Taken 
together, these results suggest that CAF-secreted exosomes mediate miR-21, 
miR-143 and miR-378e shuttling into T47D cells. 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
a 
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Figure 22. miR-21, miR-143, miR-378e are shuttled from CAF exosomes into 
breast cancer cells. T47D cells were treated 24 hours in absence (control) or in 
presence of NF exosomes (patient #6) or CAF exosomes (patients #3, #7 and 
#8). Then, a Real Time PCR was performed to evaluate miR-21, miR-143, and 
miR-378e levels in T47D cells. T47D cells treated with CAF exosomes 
exhibited increased levels of these miRs as compared to both non treated T47D 
cells and T47D cells treated with NF exosomes (a).T47D cells were cultured in 
absence (control) or in presence of exosomes isolated from cy3-miR-CAF#11 
(cy3-miR-21, cy3-miR-143, cy3-miR-378e) for 24 hours. Cy3-miRs were 
shuttled from CAF#11 exosomes into T47D cells, as shown using a confocal 
microscope (original magnification, ×60). T47D cells were stained using DAPI 
(nuclei) and ALEXA488-conjugated anti-CD63 antibody. Scale bar: 10µm. 
 
b 
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Figure 23. Z stack images of cy3-miRs shuttled from CAF exosomes to T47D 
cells. T47D cells were cultured with exosomes isolated from cy3-miR-CAF#11 
(cy3-miR-21, cy3-miR-143, cy3-miR-378e). The treated cells were stained 
using DAPI (nuclei) and ALEXA488-conjugated anti-CD63 antibody. Six 
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images for each point were acquired, and slice thickness was 1µm. Cy3-miRs 
were shuttled from CAF#11 exosomes into T47D cells, as shown by the co-
localization of cy3-miRs and Alexa488-CD63 signals. Confocal microscope 
(original magnification, ×60). Scale bar: 10µm. 
 
 
 
4.7 CAF exosomes increase stem cell and EMT markers in breast cancer 
cells 
We investigated the oncogenic role of CAF exosomes in T47D cells. 
Firstly, we tested the role of CAF conditioned medium on different biologic 
processes, such as proliferation and epithelial-mesenchymal transition (EMT). 
Notably, we found that the treatment of T47D cells with CAF conditioned 
medium enriched in exosomes increased stemness and EMT markers, whereas 
did not affect proliferation (data not shown). Thus, we decided to isolate 
exosomes from CAF (patients #3, #7 and #9) or NF (patients #5, #6 and #10) 
conditioned media to test their effects on cancer cell features such as the 
expression of stemness markers. We treated T47D cells with NF exosomes or 
CAF exosomes for 72 hours. Then, we performed a Real Time PCR to evaluate 
NANOG, OCT3/4, SOX2 (stemness genes) and SNAIL (EMT gene) levels in 
T47D cells. Interestingly, T47D cells treated with CAF exosomes displayed 
increased levels of these markers as compared to both non treated T47D cells 
and T47D cells treated with NF exosomes (Figure 24a,b,c). In addition, we 
performed a Western Blot analysis for NANOG and for E-cadherin and Zeb 
(genes involved in EMT). As shown in Figure 24a, T47D cells treated with 
CAF#3 exosomes exhibited increased levels of NANOG protein as compared 
to both non treated T47D cells and T47D cells treated with NF#5 exosomes. 
Furthermore, as shown in Figure 24b, T47D cells treated with CAF#9 
exosomes exhibited increased levels of Zeb protein and decreased levels of E-
cadherin protein as compared to both non treated T47D cells and T47D cells 
treated with NF#10 exosomes. Taken together, these data suggest that CAF 
exosomes promote EMT phenotype and stemness proprieties in breast cancer 
cells. 
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Figure 24. CAF exosomes increase stemness and EMT markers in T47D cells. 
T47D cells were cultured in absence (control) or in presence of NF#5 
exosomes (NF#5 ex) or CAF#3 exosomes (CAF#3 ex) for 72h. T47D cells 
exhibited increased levels of NANOG, OCT3/4 and SOX2 mRNAs when cells 
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were treated with CAF#3 ex respect to both non treated T47D cells and T47D 
cells treated with NF#5 ex. In addition, T47D cells displayed increased levels 
of NANOG protein only when treated with CAF#3 ex (a). T47D cells were 
cultured in absence (control) or in presence of NF#10 exosomes (NF#10 ex) or 
CAF#9 exosomes (CAF#9 ex) for 72h. T47D cells exhibited increased levels 
of SOX2 and SNAIL mRNAs when cells were treated with CAF#9 ex as 
compared to both non treated T47D cells and T47D cells treated with NF#10 
ex. Additionally, T47D cells displayed increased levels of Zeb protein and 
decreased levels of E-cadherin (E-cad) protein only when treated with CAF#9 
ex (b). T47D cells were cultured in absence (control) or in presence of NF#6 
exosomes (NF#6 ex) or CAF#7 exosomes (CAF#7 ex) for 72h. T47D cells 
exhibited increased levels of NANOG and OCT3/4 mRNAs when cells were 
treated with CAF#7 ex respect to both non treated T47D cells and T47D cells 
treated with NF#6 ex (c). 
 
 
 
4.8 CAF exosomes increase mammosphere formation ability 
To investigate the role of CAF exosomes on the stemness phenotype, 
we adopted a suspension culture of T47D cells. Briefly, we seeded T47D cells 
in non-adherent conditions (low attachment plates) and we cultured them in 
stem medium (medium supplemented with EGF, bFGF, B27) in absence or in 
presence of NF exosomes (patients #5, #6 and #10) or CAF exosomes (patients 
#3, #7 and #9). After four days, we assessed the ability of cells to form spheres. 
We observed a significant increase in the number of spheres (Figure 25a,b,c) 
and in their diameter (Figure 25d) in T47D cells treated with CAF exosomes 
compared with both non treated T47D cells and T47D cells treated with NF 
exosomes, thus indicating that CAF exosomes increase mammosphere 
formation ability. 
52 
 
 
 
Figure 25. CAF exosomes increase stemness phenotype. T47D cells were 
cultured in non-adherent conditions and in stem medium in absence (control) 
or in presence of NF exosomes (NF ex) or CAF exosomes (CAF ex). After four 
days, the capacity of cells to form spheres was assessed. T47D cells treated 
with CAF ex formed increased number of spheres as compared to both control 
and T47D cells treated with NF ex (CAF#3ex vs NF#5ex, (a), CAF#9ex vs 
NF#10ex, (b), and CAF#7ex vs NF#6ex, (c) ). Diagram showing the sphere 
diameter distribution in T47D cells (control, T47D treated with NF#6ex or 
CAF#7ex) found in 10 representative fields (d). Scale bar: 100µm. Data were 
obtained from three independent experiments and are presented as mean value 
± SD. P value was calculated using one-way ANOVA followed by 
Bonferroni’s post hoc testing. 
* p<0.05; ** p<0.01; *** p<0,001 (over control).  
§ p<0.05; §§ p<0.01; §§§ p<0,001 (over NF ex). 
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4.9 miR-21, miR-143 and miR-378e increase stem cell and EMT markers 
in breast cancer cells 
To investigate whether CAF exosomes increased stemness and EMT 
expression through their cargo miRs, we transfected T47D cells with miRs: 
scrambled (control), -21, -143, -378e, for 48 hours. Then, we performed a Real 
Time PCR to evaluate NANOG, OCT3/4, SOX2 and SNAIL mRNA levels in 
the transfected cells. Interestingly, T47D cells transfected with miRs -21, -143, 
and -378e displayed increased levels of these markers as compared to 
scrambled control (Figure 26a). In addition, we performed a Western Blot 
analysis for Nanog, Oct3/4, Zeb and Snail. As shown in Figure 26b, T47D cells 
transfected with miRs -21, -143, and -378e showed increased levels of Nanog, 
Oct3/4, Zeb and Snail proteins as compared to scrambled control. Taken 
together, these data suggest that miR-21, miR-143 and miR-378e, similarly to 
CAF exosomes, induce EMT phenotype and stemness proprieties in breast 
cancer cells. 
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Figure 26. miR-21, miR-143 and miR-378e increase stemness and EMT 
markers in T47D cells. T47D cells were transfected with miRs: scrambled (scr, 
control), -21, -143, and -378e, for 48h. T47D cells transfected with these miRs 
exhibited increased levels of NANOG, OCT3/4, SOX2 and SNAIL mRNAs as 
compared to scrambled control (a). In addition, T47D cells transfected with 
these miRs displayed increased levels of Oct3/4, Zeb, Nanog and Snail proteins 
as compared to scrambled control. Actin was used as loading control (b). 
 
 
 
4.10 miR-21, miR-143 and miR-378e increase mammosphere formation 
ability 
To investigate the role of miR-21, miR-143 and miR-378e on the 
stemness phenotype, we performed a mammosphere formation assay. Briefly, 
we transfected T47D cells with miRs: scrambled (control), -21, -143, -378e, for 
48 hours. Since these miRs are present together in CAF exosomes, we decided 
to co-transfect cells with combinations of them (miRs -21 + -143 or -21 + -
378e or -143 + -378e or -21 + -143 + -378e, final concentration: 100nM) to 
evaluate synergic effects. We seeded the transfected cells in non-adherent 
conditions and in stem medium. After four days, we assessed the ability of 
cells to form spheres. We observed a significant increase in the number of 
spheres (Figure 27a) and in their diameter (Figure 27b) in T47D cells 
transfected with miRs as compared to scrambled control. Notably, T47D cells 
transfected with miRs -21 + -143 + -378e exhibited the best significant 
capacity to form mammospheres (increased number and diameter), thus 
indicating that these miRs together increase mammosphere formation ability. 
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Figure 27. miR-21, miR-143 and miR-378e increase stemness phenotype. 
T47D cells were transfected with miRs: scrambled (scr, control), -21, -143, -
378e, alone or in combinations (final concentration: 100nM). After four days, 
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the capacity of cells to form spheres was assessed. T47D cells transfected with 
miRs formed increased number of spheres as compared to scrambled control. 
The best effects were observed when cells were transfected with combinations 
of miRs. In addition, among these miRs, the best effective in the induction of 
mammosphere formation was miR-143 (a). Diagram showing the sphere 
diameter distribution in T47D cells, found in 10 representative fields (b). Scale 
bar: 100µm (c). Data were obtained from three independent experiments and 
are presented as mean value ± SD. P value was calculated using Student’s t 
test. * p<0.05; ** p<0.01. 
 
 
 
4.11  Anti-miRs -21, -143 and -378e decrease stemness phenotype 
To further confirm the role of miRs -21, -143 and -378e in promoting 
the stemness phenotype, we transfected T47D cells with Anti-miRs: scrambled 
(control), -21, -143, -378e or -21 + -143 + -378e. As described above, we 
performed a mammosphere formation assay and observed that T47D cells 
transfected with Anti-miRs displayed a decreased ability to grow as stem-like 
aggregates (Figure 28a). Furthermore, we performed a Real Time PCR for 
SOX2 and a Western Blot analysis for genes involved in EMT, E-cadherin, 
Zeb, Snail. We found that T47D cells transfected with Anti-miRs exhibited 
decreased levels of SOX2 mRNAs respect to Anti-miR-scrambled control 
(Figure 28b). In addition, T47D cells transfected with Anti-miRs displayed 
increased levels of E-cadherin protein as compared to the control, whereas only 
the cells co-transfected with all the Anti-miRs exhibited decreased levels of 
Zeb protein. Finally, the cells transfected with Anti-miR-143 or with Anti-
miRs -21 + -143 + -378e exhibited decreased levels of Snail protein respect to 
the control (Figure 28c). Taken together, these data strongly confirm the role of 
these miRs in breast cancer stemness phenotype. 
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Figure 28. Anti-miRs -21, -143 and -378e decrease mammosphere formation 
ability and stem cell and EMT markers. T47D cells were transfected with Anti-
miRs (alone or in combinations, final concentration: 200nM) or Anti-miR-
scrambled (Anti-miRs scr, control). The cells transfected with Anti-miRs 
exhibited decreased mammosphere number as compared to the control (a). The 
cells transfected with Anti-miRs displayed decreased SOX2 mRNA levels (b) 
and increased levels of E-cadherin protein as compared to the control (c). The 
cells co-transfected with Anti-miRs -21 + -143 - +378e exhibited decreased 
levels of Zeb and Snail proteins. In addition, the cells transfected with Anti-
miR-143 showed decreased levels of Snail protein as compared to the control . 
Actin was used as loading control (c). 
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5. DISCUSSION 
 
Breast cancer is the most common cause of cancer death among 
women. Prognosis for most patients with early breast cancer is generally very 
good, however, a significant proportion (20–30%) of chemotherapy-treated 
early breast cancer patients relapses with metastatic disease (Forman et al. 
2013, Albain et al. 2012, Tjensvoll et al. 2012). Advances in standard 
treatments of BC, such as surgery, radiotherapy and chemotherapy, have 
increased patient survival, but BC incidence and the death related to this cancer 
are still high. 
Accumulating evidence indicates that signals driving tumorigenesis are 
not simply cancer cell-autonomous but involve the tumor stroma. Cancer-
associated fibroblasts represent the major components of tumor stroma and 
play an important role in promoting tumorigenic processes such as 
angiogenesis, metastasis, immune response suppression, therapy resistance in 
several solid tumors. The metastatic potential of non-small cell lung cancer 
cells has been shown to be associated with the tumor microenvironment. CAF-
induced EMT led to an increase in motility and a decrease in proliferation of 
non-small cell lung cancer cells through SMAD3-dependent up-regulation of 
the growth inhibitory gene p21CIP1 and α-SMA (Kim et al. 2013). Another 
study has demonstrated that myofibroblasts of pancreatic ductal 
adenocarcinoma had a crucial role in the immune response, innate and 
adaptive. In fact, they showed that myofibroblast-depleted tumors were 
associated with a decreased Teff/Treg ratio and a significant elevation in Ctla4 
expression (Ozdemir et al. 2014). Furthermore, a recent study has reported that 
two subtypes of CAFs of oral squamous cell carcinoma promoted cell invasion 
via different mechanisms (Costea et al. 2013). More recently, it has been 
demonstrated that cancer-associated fibroblasts induced trastuzumab resistance 
in HER2+ breast cancer (Mao et al. 2015). 
The intercommunication between tumor cells and their surrounding 
microenvironment is essential for the tumor to progress and metastasize. Many 
examples of heterotypic signaling within the tumor microenvironment involve 
classical paracrine signaling loops of cytokines or growth factors and their 
receptors. Although these signaling mechanisms undoubtedly operate as key 
means of intercellular communication within the TM, more recently, 
exosomes, membrane-derived vesicles, have been recognized as important 
mediators of intercellular communication. In fact, they carry lipids, proteins, 
mRNAs and microRNAs that can be transferred to recipient cells, thereby 
modulating cell biology. In the context of cancer, this process entails the 
transfer of cancer-promoting cellular contents between cancer cells and stromal 
cells within the tumor microenvironment or into the circulation to act at distant 
sites, thereby enabling cancer progression. For instance, it has been 
demonstrated that exosomes released by human melanoma and colorectal 
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carcinoma cells could promote the differentiation of monocytes to myeloid-
derived suppressor cells, thus supporting tumoral growth and immune escape 
(Valenti et al. 2007). An interesting work has shown that melanoma-derived 
exosomes from the primary tumor “educated” their environment to form a 
protumorigenic niche and programmed bone marrow-derived progenitors at the 
pre-metastatic site to assume a proangiogenic phenotype, thereby enhancing 
metastatic dissemination. This effect was dependent on the receptor tyrosine 
kinase MET, as its inhibition in exosomes impaired pro-metastatic effects 
(Peinado et al. 2012). Not only cancer cells, but also various stromal cells are 
capable of exosome release. For instance, Luga and colleagues (2012) have 
shown that fibroblast-secreted exosomes promoted breast cancer cell migration 
through WNT-PCP signaling. More recently, Shimoda and colleagues (2014) 
have reported that human CAFs secreted ADAM10-rich exosomes that 
promoted cell motility and activated RhoA and Notch signaling in several 
cancer cells. Taken together, these studies provide evidence of how it is useful 
to investigate the exosome-mediated communication to better understand the 
underlying mechanisms of tumorigenesis. 
In order to understand the basic biology of cancer progression and to 
develop therapeutic approaches, it is interesting to analyze the transfer of 
exosomal microRNAs to recipient cells where they can regulate tumorigenic 
processes. microRNAs are small noncoding RNAs that typically inhibit the 
translation and stability of messenger RNAs (mRNAs), controlling genes 
involved in cellular processes such as inflammation, cell-cycle regulation, 
stress response, differentiation, apoptosis, and migration. Their deregulation 
has been shown to play an essential role in the development and progression of 
cancer. Compared with those in normal tissue, miRNAs in malignant tissue are 
up- or down-regulated; these miRNAs can be considered oncogenes or tumor 
suppressors, respectively, and can affect all the hallmarks of cancer. Extensive 
analyses have highlighted the causative roles of many miRNAs in cancer by 
using either human cancer cells or genetically engineered animal models. For 
example, transgenic expression of miR-155 or miR-21 and deletion of miR-
15/16 are sufficient to initiate lymphoma-genesis in mice. Conversely, 
systemic delivery of selected miRNAs, including let-7, miR-26a, miR-34a, and 
miR-143/145, inhibits tumor progression in vivo (Garofalo et al. 2014). 
Recently, it has emerged that, in addition to cellular miRNA deregulation, 
exosomal miRNA deregulation could play a crucial role in cancer. For 
example, a study has shown that leukemia cells could release miR-92a via 
exosomes into human umbilical vein endothelial cells, leading to increased cell 
migration and tube formation (Umezu et al. 2013). Another study has 
elucidated how miR-223 secreted by tumor-associated macrophages promoted 
the invasion of breast cancer cells, through the disruption of the Mef2c-β-
catenin pathway (Yang et al. 2011). Moreover, it has been reported that miR-
21 and miR-29a secreted by lung cancer exosomes bound to murine TLR7 and 
human TLR8 and triggered a Toll-like receptor (TLR)-mediated prometastatic 
inflammatory response that could lead to tumor growth and metastasis (Fabbri 
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et al. 2012). More recently, an interesting work has demonstrated that CAF-
derived miR-409 induced tumorigenesis, epithelial-to-mesenchymal transition 
and stemness of the epithelial prostate cancer cells in vivo (Josson et al. 2014). 
Therefore, these works strongly suggest that one alternative mechanism 
of the promotion of breast cancer progression by CAFs may be through cancer-
associated fibroblast-secreted exosomes, which would deliver oncogenic miRs 
to breast cancer cells. To this aim, for the first time, we characterized exosomal 
miRs of breast cancer-associated fibroblasts. Notably, we found that in CAF 
exosomes the levels of miR-21-5p, miR-378e, and miR-143-3p were increased 
as compared to normal fibroblast exosomes, whereas we did not observe an up-
regulation of these miRs in CAF cells as compared to NF cells, indicating a 
selective mechanism of exosomal miRNA sorting. We visualized, by 
immunofluorescence experiments, the transfer of PKH26-labeled-exosomes 
from fibroblasts to breast cancer cells. Furthermore, we confirmed the transfer 
of these miRs from CAF exosomes to T47D breast cancer cells in our system 
with two different approaches: we visualized cy3-labeled-miRs (cy3-miR-21-
5p, cy3-miR-143-3p, cy3-miR-378e) shuttling from CAF exosomes into T47D 
cells, and we observed the increase of these miR levels in breast cancer cells 
treated with CAF exosomes. Then, we demonstrated that TGF-β, in addition to 
its direct role in the activation of normal fibroblasts to CAFs, could increase 
the levels of these miRs in normal fibroblast exosomes, suggesting that the up-
regulation of these miRs is a signature of TGF-β activated fibroblasts. Taken 
together, these data strongly show a crosstalk between CAFs and BC cells 
mediated by miR-21-5p, miR-143-3p and miR-378e. 
miR-21 is a well characterized oncogenic miR. In our group, we have 
found that miR-21 regulates therapy resistance in glioma cells (Quintavalle et 
al. 2013). Several works have demonstrated the role of miR-21 in cancer 
progression and diagnosis. In particular, in breast cancer, it has been reported 
that miR-21 correlates with poor prognosis, regulates EMT phenotype and 
promotes cancer cell proliferation and invasion (Han et al. 2012, Dong et al. 
2014, Song et al. 2010). It has also been found up-regulated in the serum of 
breast cancer patients (Li et al. 2014). The tumorigenic role of miR-143-3p 
depends on cancer types. miR-143-3p have been found up-regulated in a large 
cohort of patients including 88 colorectal cancer tumors, suggesting that have 
an oncogenic role (Schee et al. 2013). On the contrary, it has been shown 
down-regulated in gastric cancer, indicating a tumor suppressive role (Wu et al. 
2013). miR-378e has not been studied, so far for oncogenic/oncosuppressive 
role.  
Many tumors, including breast cancer, are maintained by a 
subpopulation of cells that display stem cell properties, known as cancer stem 
cells (CSCs). CSCs are defined by their ability to initiate tumors in immune-
compromised mice upon serial passage, a demonstration of self renewal, as 
well as their ability to differentiate into the non–self-renewing cells forming 
the tumor bulk (Korkaya et al. 2008, Ginestier et al. 2007). Analogous to the 
regulation of normal stem cells by their “niche”, CSCs are regulated by, and in 
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turn regulate, cells within the tumor microenvironment. Several studies have 
provided evidence that these CSCs mediate tumor metastasis and contribute to 
treatment resistance and relapse (Li et al. 2008, Liu et al. 2010). Bi-directional 
paracrine signals coordinately regulate tumorigenic cell populations including 
CSCs. Tumorigenic cells in turn produce factors that attract and regulate the 
diverse variety of cell types that constitute the tumor microenvironment. For 
instance, in human breast cancers, mesenchymal stem cells may be recruited 
from the bone marrow to sites of growing tumor, where they interact with 
breast CSCs through cytokine loops involving IL-6 and CXCL7, thereby 
promoting breast cancer metastasis (Liu et al. 2011, Karnoub et al. 2007). 
Therefore, strategies designed to specifically target the interaction between the 
CSCs and their microenvironment represent an important approach to 
improving patient outcome. Recent findings have shown that hierarchically 
organized cell populations are more plastic than previously imagined (Chaffer 
et al. 2011, Chaffer et al. 2013, He et al. 2011). Thus, epithelial cells may 
dedifferentiate and thereby enter back into the stem cell pool. Moreover, this 
plastic model of tumorigenicity suggests that the pool of cells capable of 
successfully seeding a metastatic outgrowth is not restricted to the existing 
pool of CSCs within a primary tumor. Instead, the more differentiated progeny 
of these CSCs may also initiate metastases if it is capable of reverting to the 
tumor-initiating CSC state at distant sites of dissemination. Thus, therapies 
aimed at targeting the CSCs within a tumor will not be curative if the pool of 
CSCs can be continuously regenerated from plastic non cancer stem cells that 
are capable of dedifferentiating and reentering the CSC state. In this scenery, to 
discover the underlying mechanisms that promote dedifferentiation processes 
could provide new targets for therapeutic strategies. 
In our study, we wondered whether CAF exosomes and the identified 
exosomal miRs could promote dedifferentiation process of BC cells. For the 
first time, we provided evidence of the role of CAF exosomes and their miR 
contents in the induction of stemness phenotype in breast cancer cells. In fact, 
T47D cells exposed to CAF exosomes or transfected with the identified miRs 
exhibited a significantly increased capacity to form mammospheres (breast 
cancer cells enriched in stem-like cells that grown as spheres). 
Notably, accumulating evidence indicates that the expression of Oct3/4, 
Nanog, and Sox2 transcription factors has a strong correlation with CSCs: 
knockdown of these genes decreased tumor sphere formation and inhibited 
tumor formation in xenograft tumor models (Leis et al 2012, Wang et al. 2014). 
The transdifferentiation of epithelial cells into mesenchymal cells, a process 
known as epithelial-mesenchymal transition (EMT), is integral in development, 
wound healing and stem cell behavior, and contributes pathologically to 
fibrosis and cancer progression. This switch in cell differentiation and behavior 
is mediated by key transcription factors, including Snail and Zeb, and is 
characterized by the loss of epithelial marker expressions, such as E-cadherin. 
Epithelial-mesenchymal transition and mesenchymal-epithelial transition have 
been closely linked to ‘stemness’ in development and cancer. EMT has also 
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been associated with epithelial and carcinoma stem cell properties. Expression 
of Snail in breast epithelial cells induces a mesenchymal cell population 
marked with a stem-like phenotype, which is similar to that observed in 
epithelial stem cells. The correlation of EMT with stemness extends to 
carcinomas. In breast carcinomas, induction of EMT promotes the generation 
of CSCs that are able to form mammospheres, and, similarly, CSCs isolated 
from tumors express EMT markers (Mani et al. 2008, Scheel et al. 2012). 
Interestingly, we found that T47D cells exposed to CAF exosomes or 
transfected with the identified miRs also displayed increased stem cell markers, 
such as SOX2, Nanog and Oct3/4, and promoted EMT markers, decreased E-
cadherin and increased Snail and Zeb. Our findings showed that, among these 
miRs, the most effective was miR-143-3p, whereas the best effect in promoting 
mammosphere formation was observed when breast cancer cells were co-
transfected with combinations of these miRs, thus indicating that they act 
together. On the contrary, breast cancer cells co-transfected with combinations 
of the Anti-miRs displayed a strong reduction of mammosphere formation 
capacity, EMT and stemness markers, thereby underlying a good strategy to 
prevent dedifferentiation of breast cancer cells. 
 In summary, we conclude that CAF exosomes regulate the stemness 
phenotype of breast cancer cells and our data suggest that this effect could be 
fostered by exosome-mediated delivery of oncogenic miRs, as they together 
promote stem-like phenotype. Our data clearly provide insights into the 
mechanisms underlying the stemness maintenance in breast cancer and propose 
miR-21-5p, miR-143-3p and miR-378e as new therapeutic molecular targets. 
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6. CONCLUSIONS 
 
In conclusion, this study demonstrates that functional miRNAs can be 
transferred from cancer-associated fibroblasts to breast cancer cells. Exosomes 
secreted from CAFs shuttle miR-21-5p, miR-143-3p and miR-378e into breast 
cancer cells. Interestingly, CAF exosomes promote the dedifferentiation of 
breast cancer cells through the up-regulation of stemness and EMT markers, 
thereby enabling stemness maintenance. Furthermore, the overexpression of 
the identified miRs in breast cancer cells enhances the stemness phenotype and 
increases stemness and EMT markers. On the contrary, the down-regulation of 
these miRs, through specific Anti-miRs, prevents the dedifferentiation of breast 
cancer cells through the down-regulation of stemness and EMT markers. Thus, 
our study provides insights into the mechanisms of cell-cell interactions 
through which CAFs regulate breast cancer progression via the exosomal-
mediated delivery of oncogenic miRNAs. In addition, our data strongly provide 
evidence of new therapeutic molecular targets. 
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Abstract
Glioblastoma multiforme (GBM) is one of the most deadly types of cancer. To date, the best clinical approach for
treatment is based on administration of temozolomide (TMZ) in combination with radiotherapy. Much evidence
suggests that the intracellular level of the alkylating enzyme O6-methylguanine–DNA methyltransferase (MGMT)
impacts response to TMZ in GBM patients. MGMT expression is regulated by the methylation of its promoter.
However, evidence indicates that this is not the only regulatory mechanism present. Here, we describe a hitherto
unknown microRNA-mediated mechanism of MGMT expression regulation. We show that miR-ββ1 and miR-βββ are
upregulated in GMB patients and that these paralogues target MGMT mRNA, inducing greater TMZ-mediated cell
death. However, miR-ββ1/miR-βββ also increase DNA damage and, thus, chromosomal rearrangements. Indeed,
miR-ββ1 overexpression in glioma cells led to an increase in markers of DNA damage, an effect rescued by re-
expression of MGMT. Thus, chronic miR-ββ1/βββ-mediated MGMT downregulation may render cells unable to repair
genetic damage. This, associated also to miR-ββ1/βββ oncogenic potential, may poor GBM prognosis.
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Introduction
Glioblastoma multiforme (GBM) is the most common and
deadly primary tumor of the central nervous system. Despite
several therapeutic advances, the prognosis for GBM remains
poor, with a median survival lower than 15 months [1,β].
Currently, first-line therapy for GBM comprises surgery with the
maximum feasible resection, followed by a combination of
radiotherapy and treatment with the alkylating agent
temozolomide (TMZ), also referred to by its brand name
Temodal [γ,4,5]. TMZ is a methylating agent that modifies DNA
in several positions, one of them being O6-methylguanine MeG
(O6MeG) [6]. If the methyl group is not removed before cell
division, this modified guanine preferentially pairs with thymine
during DNA replication, triggering the DNA mismatch repair
(MMR) pathway, DNA double-strand breaks, and, therefore,
the apoptotic pathway [7,8]. O6-methylguanine–
methyltrasferase (MGMT) is a suicide cellular DNA repair
enzyme ubiquitously expressed in normal human tissues.
MGMT does not act as a part of a repair complex but works
alone [9]. To neutralize the cytotoxic effects of alkylating
agents, such as TMZ, it rapidly reverses alkylation at the O6
position of guanine, transferring the alkyl group to an internal
cysteine residue in its active site. In this form, the enzyme is
inactive and, thus, requires de novo protein synthesis. In
tumors, high levels of MGMT activity are associated with
resistance to alkylating agents [10]. In contrast, epigenetic
silencing of MGMT gene expression by promoter methylation
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results in sensitization to therapy [11,1β]. However, some
studies have reported that MGMT promoter methylation does
not always correlate with MGMT expression and with response
to therapy [1γ,14]. Therefore, the existence of other
mechanisms of MGMT regulation should be postulated.
MicroRNAs (miRs) are small regulatory molecules that have
a role in cancer progression and in tumor therapy response
[15,16]. By negatively regulating the expression of their targets,
miRs can act as tumor suppressors or oncogenes [17]. miRs
may also regulate DNA damage response and DNA repair,
interfering with the response to chemotherapy or radiotherapy
[18]. Several studies have indicated that the modulation of miR
expression levels is a possible therapeutic strategy for cancer.
The paralogues miR-ββ1 and miR-βββ have frequently been
found to be dysregulated in glioblastoma and astrocytomas
[19,β0,β1,ββ]. Their upregulation increases glioma cell
proliferation, motility, and in vivo growth in mouse models.
miR-ββ1/βββ have also been shown to be implicated in cellular
sensitivity to tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL)-treatment [βγ,β4,β5]. In this manuscript, we
provide evidence that miR-ββ1 and miR-βββ regulate MGMT
expression levels in glioblastoma, increasing the response to
TMZ, but due to their oncogenic potential, affect overall patient
survival negatively.
Materials and Methods
Cell culture and transfection
U87MG, T98G, LN4β8, LNγ08, A17β, and HEK-β9γ cells
were grown in DMEM. LNββ9 were grown in Advanced DMEM
(Gibco, Life technologies, Milan, Italy). T98G, U87MG, and
LNββ9 were from ATCC (LG Standards, Milan Italy); LN4β8,
LNγ08, and A17β were kindly donated by Frank Furnari (La
Jolla University). Media were supplemented with 10% heat-
inactivated fetal bovine serum (FBS) -5% FBS for LNββ9 -β
mM L-glutamine, and 100 U/ml penicillin/streptomycin. All
media and supplements were from Sigma Aldrich (Milan, Italy).
For overexpression of miRs, cells at 50% confluency were
transfected using Oligofectamine (Invitrogen, Milan, Italy) and
100nM pre-miR-ββ1 or pre-miR-βββ, a scrambled miR or anti-
miR-ββ1/βββ (Applied Biosystems, Milan, Italy). For
overexpression of MGMT, cells were transfected using
Lipofectamine and Plus Reagent with 4 µg of MGMT cDNA
(Origene, Rockville MD USA). Temozolomide was purchased
from Sigma Aldrich (Milan, Italy).
Human Glioma samples
A total of γ4 formalin-fixed, paraffin-embedded (FFPE) tissue
samples were collected from the archives of the Department of
Pathology, University Hospital of Kuopio, Finland. Permission
to use the material was obtained from the National Supervisory
Authority for Welfare and Health of Finland, and the study was
accepted by the ethical committee of the Northern Savo
Hospital District, Kuopio, Finland.
Primary cell cultures
Glioblastoma specimens were obtained as previously
described [19]. Samples were mechanically disaggregated, and
the lysates grown in DMEM-F1β medium supplemented with
10% FBS, 1% penicillin streptomycin, and β0 ng/ml epidermal
growth factor (EGF; Sigma-Aldrich, Milan, Italy). To determine
the glial origin of the isolated cells, we stained the cultures for
glial fibrillary acidic protein (GFAP), a protein found in glial
cells.
Protein isolation and Western blotting
Cells were washed twice in ice-cold PBS and lysed in JS
buffer (50 mM HEPES pH 7.5 containing 150 mM NaCl, 1%
Glycerol, 1% Triton X100, 1.5mM MgClβ, 5mM EGTA, 1 mM Na
γVO4, and 1X protease inhibitor cocktail). Protein concentration
was determined by the Bradford assay (BioRad, Milan, Italy)
using bovine serum albumin (BSA) as the standard, and equal
amounts of proteins were analyzed by SDS-PAGE (1β.5%
acrylamide). Gels were electroblotted onto nitrocellulose
membranes (GE Healthcare, Milan, Italy). For immunoblot
experiments, membranes were blocked for 1 hr with 5% non-fat
dry milk in Tris-buffered saline (TBS) containing 0.1%
Tween-β0, and incubated at 4°C overnight with primary
antibody. Detection was performed by peroxidase-conjugated
secondary antibodies using the enhanced chemiluminescence
system (GE Healthcare, Milan, Italy). Primary antibodies used
were: anti-ȕ-actin from Sigma-Aldrich (Milan Italy); anti-
caspase-γ and anti-PARP from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA), anti-ȖHβAX from Millipore (Milan,
Italy), anti-p5γ, pser15 p5γ, and phosphorylated-ATM from Cell
Signaling Technology (Milan, Italy).
RNA extraction and Real-Time PCR
Cell culture: Total RNA (microRNA and mRNA) were
extracted using Trizol (Invitrogen, Milan, Italy) according to the
manufacturer’s protocol.
Tissue specimens
Total RNA (miRNA and mRNA) from FFPE tissue specimens
was extracted using RecoverAll Total Nucleic Acid isolation Kit
(Ambion, Life Technologies, Milan, Italy) according to the
manufacturer’s protocol. Reverse transcription of total miRNA
was performed starting from equal amounts of total RNA/
sample (1µg) using miScript reverse Transcription Kit (Qiagen,
Milan, Italy), and with SuperScript® III Reverse Transcriptase
(Invitrogen, Milan, Italy) for mRNA. Quantitative analysis of
MGMT, ȕ-actin (as an internal reference), miR-ββ1, miR-βββ,
and RNU5A (as an internal reference) were performed by
RealTime PCR using specific primers (Qiagen, Milan, Italy),
miScript SYBR Green PCR Kit (Qiagen, Milan, Italy), and iQTM
SYBR Green Supermix (Bio-Rad, Milan, Italy), respectively.
The reaction for detection of mRNAs was performed as follows:
95°C for 15’, 40 cycles of 94°C for 15″, 60°C for γ0″, and 7β°C
for γ0″. The reaction for detection of miRNAs was performed as
follows: 95°C for 15’, 40 cycles of 94°C for 15″, 55°C for γ0″,
and 70°C for γ0″. All reactions were run in triplicate. The
threshold cycle (CT) is defined as the fractional cycle number
MicroRNA, MGMT, Glioma and Temozolomide Resistance
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at which the fluorescence passes the fixed threshold. For
relative quantization, the β(-ΔCT) method was used as previously
described [β6]. Experiments were carried out in triplicate for
each data point, and data analysis was performed by using a
Bio-Rad software (Bio-Rad, Milan, Italy).
Luciferase assay
The γ’ UTR of the human MGMT gene was PCR amplified
using the following primers: MGMT-Fw:
5’TCTAGAGTATGTGCAGTAGGATGGATGγ’; MGMT-Rv: 5’
TCCAGAGCTACAGGTTTCCCTTCCγ’, and cloned
downstream of the Renilla luciferase stop codon in pGLγ
control vector (Promega, Milan, Italy). A deletion was
introduced into the miRNA-binding sites with the QuikChange
Mutagenesis Kit (Stratagene, La Jolla CA USA) using the
following primers: MGMT-mut Fw: 5’
CTATATCCAAAAGGGAAACCTGTAGCTCTTGC γ’. MGMT-
mut Rw: 5’- GCAGAGCTACACGTTTCCCTTTTGGATATAG γ’.
HEK-β9γ cells were co-transfected with 1.βµg of plasmid and
400 µg of a Renilla luciferase expression construct, pRL-TK
(Promega, Milan, Italy), with Lipofectamine β000 (Invitrogen,
Milan, Italy). Cells were harvested β4 hrs post-transfection and
assayed with Dual Luciferase Assay (Promega, Milan, Italy)
according to the manufacturer’s instructions. Three
independent experiments were performed in triplicate.
Cell death quantification
Cell viability was evaluated with the CellTiter 96 AQueous
One Solution Cell Proliferation Assay (Promega, Milan, Italy)
according to the manufacturer’s protocol. Metabolically active
cells were detected by adding β0 µL of MTS to each well. After
β hrs of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy). For caspase-γ inhibition
experiments, ZVAD-Fmk was purchase from Calbiochem.
Comet assay
Alkaline comet assay was performed accordingly to
manufacturer’s instructions (Trevigen, Gaithersburg, Maryland,
USA). Briefly, 1βx104 glioblastoma cell lines were transfected
with miRs or MGMT cDNA and then treated with TMZ in 6-well
plates. Cells were collected and then combined with
LMAgarose. The mixture was applied to Comet slides and kept
at 4°C in the dark for 10’. The slides were immersed in pre-
chilled lysis buffer for γ0 min. The slides were washed and then
electrophoresis was carried out. The slides were fixed in 70%
ethanol for 5 min and let dry overnight. SYBR green was added
and comets were photographed at 100 x microscopes (Carl
Zeiss Inc., NY, USA).
γH2AX flow cytometric analysis
Treated cells were fixed with β% paraformaldehyde for 1 hr.
Fixed cells were permeabilized with 0.1% Triton-X100/PBS for
5 min on ice. Blocking was done in PBS+β% BSA. Anti-
phosphorylated HβAx antibody(Ser1γ9, ȖHβAx, Millipore,
Milan, Italy) was diluted in PBS and then FITC-conjugated goat
anti-mouse antibody (Santa cruz Biotechnology, CA, USA) was
used. Cells were analyzed with a Becton Dickinson FACScan
flow cytometer.
Caspase Assay
The assay was performed using the Colorimetric CaspACETM
Assay System, (Promega, Milan, Italy) as reported in the
instruction manual. Briefly, T98G cells were transfected with
miR-ββ1 and/or MGMT cDNA, plated in 96-well plates, and
then treated with γ00 µMol of temozolomide or with 10 µMol of
ZVAD-Fmk. After treatments, 100 µl caspase-γ/-7 reagent was
added to each well for 1 hr in the dark. The plates were
analyzed in a Multilabel Counter (BioTek, Milan, Italy).
MGMT Methylation Analysis
DNA methylation status in the CpG island of MGMT was
established by PCR analysis of bisulfite modified genomic
DNA, which induces chemical conversion of unmethylated, but
not methylated, cytosine to uracil. DNA was extracted from cell
lines using the DNeasy blood and tissue kit (Qiagen, Milan,
Italy). DNA (1 µg) was modified with sodium bisulfite using the
EZ DNA methylation-gold kit (Zymo Research, CA, USA)
according to the manufacturer’s instructions. Methylation-
specific polymerase chain reaction (MSP) was performed with
primers specific for either methylated or the modified
unmethylated DNA. Primer sequences for the unmethylated
reaction were 5'TTTGTGTTTTGATGTTTGTAGGTTTTTGTγ'
(forward primer) and
5'AACTCCACACTCTTCCAAAAACAAAACAγ' (reverse
primer), and for the methylated reaction they were
5'TTTCGACGTTCGTAGGTTTTCGCγ' (forward primer) and
5'GCACTCTTCCGAAAACGAAACGγ' (reverse primer.) The
annealing temperature was 59°C. The cell line SW48 and in
vitro methylated DNA (CpGenome Universal Methylated DNA,
Millipore) were used as a positive control for the methylation of
MGMT and DNA from normal lymphocytes used as a negative
control. Controls without DNA were used for each set of
methylation-specific PCR assays. The methylation-specific
PCR product was loaded directly onto β% agarose gels,
stained with syber safe, and examined under ultraviolet
illumination.
Colony Assay
Cells were transfected with scrambled miR or miR-ββ1 for β4
hrs, harvested, and β.4 x104 cells plated in 6-well plates. After
β4 hrs, cells were treated with γ00 µMol TMZ for β4 hrs, as
indicated. Cells were transferred to 100-mm dishes and grown
for 6 days. Finally, the cells were colored with 0.1% crystal
violet dissolved in β5% methanol for β0 min at 4°C. Dishes
were washed with water, left to dry on the bench, and then
photographs taken.
Statistical analysis
Student’s t test and nonparametric Mann-Whitney tests were
used to determine differences between values for normally
and, respectively, not normally distributed variables. A
probability level <0.05 was considered significant throughout
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the analysis. Data were analyzed with GraphPad Prism (San
Diego, CA, USA) for Windows.
Results
Sensitivity of human glioma cell lines to temozolomide
We analyzed the sensitivity to TMZ of human glioma cell
lines by exposing the cells to γ00 µMol TMZ for 48 hours and
then assessing cell viability with the MTT assay (Figure 1A).
We observed different TMZ sensitivities, which correlated with
MGMT levels analyzed by Western blot (Figure 1B). We also
observed an inverse correlation between the level of MGMT
(Figure 1B) and miR-ββ1 expression in glioma cell lines (Figure
1C). An RNA hybrid alignment bioinformatics search identified
a possible binding site for miR-ββ1/βββ at position 970 of the γ’
UTR of MGMT.
To examine whether miR-ββ1/βββ interfered with MGMT
expression by directly targeting the predicted γ’ UTR region,
we cloned this region downstream of a luciferase reporter gene
in the pGLγ vector. HEK-β9γ cells were co-transfected with the
reporter plasmid plus the negative control miR (scrambled
miR), miR-ββ1, or miR-βββ. Only transfection of either miR-ββ1
or miR-βββ with the wild-type MGMT-γ’UTR reporter plasmid
led to a significant decrease of luciferase activity. On the
Figure 1.  TMZ sensitivity and MGMT and miR-221/222
expression in glioma cells.  (A) Glioma cells were treated
with TMZ (γ00µMol) for β4 hr. Cell viability was evaluated with
an MTT assay. (B) Western blot analysis of MGMT expression
in glioblastoma cells. (C) Real time PCR of miR-ββ1 expression
in glioblastoma cells. (D) RNA Hybrid prediction analyzes of
miR-βββ, miR-ββ1, and MGMT γ’ UTR. In bold are shown the
mutated oligonucleotides. Luciferase activity of HEK-β9γ cells
transiently co-transfected with the luciferase reporter containing
wild-type MGMT-γ’UTR or mutant MGMT-γ’UTR in the
presence of pre-miR-βββ, miR-ββ1, or scrambled
oligonucleotide. Representative of at least three independent
experiments. *** p<0.001 versus control, ** p<0,00γ7 versus
control.
doi: 10.1γ71/journal.pone.0074466.g001
contrary, co-expression of the scrambled miR had no effect
(Figure 1D). In addition, miR-ββ1/βββ’s effect on the promoter
of MGMT was reduced with the mutant MGMT-γ’UTR reporter,
in which the seed sequence was mutated. Together, these
results demonstrate that miR-ββ1/βββ directly target
MGMT-γ’UTR, thereby reducing MGMT expression.
miR-221/222 target MGMT protein and mRNA
In order to establish a causal link between miR-ββ1/βββ and
MGMT expression, we transfected T98G cells with either pre-
miR-ββ1 or pre-miR-βββ for 7β hrs and then analyzed MGMT
levels by Western blot and real time-PCR. Upon miR
transfection, MGMT protein and mRNA were downregulated
(Figure βA). In contrast, MGMT expression was increased
upon transfection with anti-miR-ββ1 or -βββ in U87MG cells
(Figure βB). Similarly, miR-ββ1/βββ, induced downregulation of
MGMT in LN4β8 cells, another TMZ-resistant glioma cell line
(Figure βC), and in Aγ75 cells, a TMZ-resistant melanoma cell
line (Figure βD). Since MGMT expression is mainly dependent
on the methylation status of its promoter [β7], we determined if
miR-ββ1/βββ acted by modulating MGMT promoter
methylation. To this end, we performed a bisulfite modification
assay by PCR using specific primers for both methylated and
unmethylated MGMT promoter. As shown in Figure βE,
miR-ββ1/βββ expression in T98G cells, or anti-miR expression
in U87MG cells, did not modify the methylation profile of the
MGMT promoter.
miRs-221/222 modulate TMZ sensitivity in glioma cells
To verify if miR-ββ1/βββ play a role in the modulation of TMZ
sensitivity because of their effects on MGMT expression, we
characterized the viability of T98G, LN4β8, and Aγ75 cells
transfected with miR-ββ1/βββ and then treated with TMZ for β4
hrs. As shown in Figure γA, miR-ββ1/βββ transfection
increased the response to TMZ. These results were also
confirmed by proliferation and colony assays (Figure γB and
γC). To establish a causal link between miR-ββ1 expression
and MGMT downregulation, we performed a rescue experiment
with simultaneous overexpression of miR-ββ1 and MGMT
cDNA in two different cell lines (T98G and LN4β8). As shown in
Figure γD, the effect of miR-ββ1 on TMZ response was
abolished by MGMT overexpression. We then verified in nine
different glioblastoma primary cell lines and in six glioma cell
lines any correlation between miR-ββ1 expression and TMZ
sensitivity. As shown, TMZ sensitivity positively correlated with
the expression level of miR-ββ1 (Figure γE).
miR-221 promotes apoptotic cell death
In order to evaluate the mechanism of TMZ-induced cell
death, we assessed the presence of apoptotic cells by PI
staining and flow cytometry upon miR-ββ1 transfection and
TMZ treatment. We found that TMZ increased apoptotic cell
death in miR-ββ1-overexpressing cells compared with control
cells. Interestingly, this effect was rescued by the co-
expression of MGMT cDNA with miR-ββ1 (Figure 4A).
Caspase-γ/7 activation assay further confirmed the
involvement of the apoptotic machinery. As shown in Figure
4B, miR-ββ1 expression increased caspase-γ activity upon
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TMZ treatment, while the co-expression of MGMT cDNA with
miR-ββ1 abolished this effect. Simultaneous treatment with the
caspase inhibitor ZVAD-fmk and TMZ was able to decrease
caspase activity, confirming that TMZ induced cell death by a
caspase-mediated mechanism. Caspase-γ activation,
observed by Western blot in miR-ββ1-transfected cells after β4
hrs of TMZ treatment, was rescued by MGMT cDNA (Figure
4C). Coherently, we observed an increase in cell viability after
miR-ββ1 transfection and simultaneous treatment with TMZ
and ZVAD-fmk (Figure 4D).
miR-221 promotes DNA damage after TMZ treatment
MGMT activity repairs DNA by removing DNA adducts
caused by TMZ treatment. The absence of MGMT increases
cell death upon exposure to TMZ, but, as a long-term effect,
may increase DNA damage, and thus the accumulation of
mutations. We investigated whether miR-ββ1 may increase
DNA damage upon TMZ treatment by down-modulating MGMT
expression. This was assessed by a comet assay, which
quantifies double-stranded DNA (dsDNA) breaks, in T98G cells
transfected with miR-ββ1 or a scrambled sequence and then
treated with TMZ at different times. We found that miR-ββ1
produced a significant enhancement of dsDNA breaks (Figure
5A). To strengthen our hypothesis, we looked for the
phosphorylation status of histone HβAX (ȖHβAX) at Ser1γ9,
which reflects dsDNA break formation. As shown in Figure 5B,
Figure 2.  miR-221/222 target MGMT.  (A) Western blot
analysis and real time PCR of MGMT protein and RNA after
miR-ββ1/βββ transfection of T98G cells. (B) Western blot
analysis and real time PCR of MGMT protein and RNA after
anti-miR-ββ1 and -βββ transfection of U87MG cells. (C)
Western blot of MGMT expression upon miR-ββ1 transfection
of LN4β8 cells. (D) Western blot analysis of MGMT expression
in T98G cells, as a control, and the melanoma cell line Aγ75
upon miR-ββ1 transfection. (E) Analysis of methylation status
of MGMT promoter in T98G and U87MG upon miR- or anti-
miR-ββ1/βββ transfection. U is for the un-methylated form, M
for methylated form, NL is for normal lymphocytes, used as
control.
doi: 10.1γ71/journal.pone.0074466.g00β
miR-ββ1 significantly increased ȖHβAX, as assessed by
immunocytofluorescence (upper panel) or by Western blot
(lower panel), suggesting that miR overexpression may induce
DNA damage. This effect was even stronger in the presence of
TMZ, but was rescued by MGMT cDNA (Figure 5B, middle
panel). Furthermore, we also observed an increase of other
DNA damage markers, such as P-ATM, P-p5γser15 and PARP
cleavage, upon miR-ββ1 transfection; this was even stronger
upon treatment with both miR-ββ1 and TMZ (Figure 5C). These
effects were rescued by the simultaneous expression of MGMT
with miR-ββ1. Taken together, these data suggest that the
targeting of MGMT by miR-ββ1 increases DNA damage. This
effect was amplified by TMZ treatment.
MGMT and miR-221 expression in glioblastoma
patients
We then evaluated the expression of MGMT and miR-ββ1 in
human glioblastoma samples. Patients were clustered into two
separate groups: a long survival (survival >15 months) group
and a short survival (survival <15 months) group, according to
common classification [β].
We first analyzed the methylation profile of the MGMT
promoter, and then MGMT mRNA and miR-ββ1 levels. We
performed methylation-specific PCR (MSP) on γγ human
Figure 3.  miR-221 modulates TMZ sensitivity.  (A) Cell
viability of T98G, LN4β8, and Aγ75 cells transfected with
miR-ββ1 and miR-βββ upon TMZ treatment (γ00 µMol) for β4
hrs. **p value<0.008β versus scr column, ***p value<0.005
versus scr column. (B) Growth curve of T98G and LN4β8 cells
transfected or not with miR-ββ1 after β4 hrs of treatment with
TMZ. (C) Colony assay of T98G and LN4β8 cells transfected
with miR-ββ1 and then treated for β4 hrs with TMZ (γ00 µMol).
Cells were left to grow for 6 days after treatment removal. (D)
MGMT expression rescues cell viability after TMZ treatment in
T98G and LN4β8 cells overexpressing miR-ββ1 **p
value<0.008β versus untransfected MGMT column. (E)
Correlation between miR-ββ1 expression and TMZ sensitivity in
nine primary glioblastoma cell lines and in six glioblastoma cell
lines.
doi: 10.1γ71/journal.pone.0074466.g00γ
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glioblastoma paraffin-embedded tissues, and found β7 to be
unmethylated and 4 to be methylated (samples β, β1, ββ, and
β8) (Figure S1). For two samples (#γ1 and #γβ), it was not
possible to define the MGMT promoter methylation profile. We
then analyzed the effect of miR-ββ1 on MGMT regulation
among 15 unmethylated samples from which we obtained
sufficient RNA for real time PCR analysis. We identified 4 long-
(#1, #4, #10, and #14) and 11 short- (#6, #7, #8, #1β, #1γ, #17,
#18, #βγ, #β5, #γβ, and #γγ) survival patients. We found that
the short-survival group exhibited a higher miR-ββ1 level and a
lower MGMT level compared with the long-survival group
(Figure 6 A,B). These data supports our in vitro evidence of an
inverse correlation between miR-ββ1 and MGMT expression.
Furthermore, this observation identifies miR-ββ1 as a negative
prognostic factor for survival.
Discussion
Much evidence suggests that the intracellular level of the
alkylating enzyme MGMT affects TMZ response in GBM
patients [10,11]. Low levels of MGMT are associated with a
better TMZ response, because in the absence of MGMT the
cells are not able to repair the TMZ-induced base mismatch.
Figure 4.  miR-221 promotes DNA damages upon TMZ
treatment.  (A) Apoptotic cell death assessed by FACS in
T98G cells transfected with miR-ββ1 or scrambled sequence
and MGMT and treated with TMZ for β4 hrs. *** p value< 0.005
versus untrasfected MGMT column. (B) Active caspase-γ
quantification in T98G cells as indicated and treated with TMZ
for β4 hrs in the presence or absence of γ hrs pre-treatment
with ZVAD-fmk. (C) Upper panel Time course analysis of
caspase-γ activation upon TMZ treatment in T98G cells
transfected with miR-ββ1 or with scrambled sequence. Lower
panel Western blot analysis of caspase-γ activation after
miR-ββ1 and MGMT transfection. (D) Cell viability of T98G
cells transfected with miR-ββ1 or with scrambled sequence
treated with TMZ for β4 hrs in the presence or absence of γ hrs
pre-treatment with ZVAD-fmk. ** p value< 0.00γ4 versus only
treated TMZ column, Student’s t test.
doi: 10.1γ71/journal.pone.0074466.g004
Hence, double-strand DNA breaks, DNA mismatch repair, and
the apoptotic pathway are activated. MGMT expression is
regulated by the methylation of its promoter. MGMT promoter
methylation lowers MGMT levels and accounts for a greater
TMZ response when associated with radiotherapy. However, a
fraction of patients with unmethylated MGMT show some TMZ
response, suggesting that promoter methylation is not the only
regulatory mechanism of MGMT expression [1γ,14].
In the present study, we addressed this specific issue by
investigating the involvement of miRs in MGMT regulation.
First, we characterized TMZ sensitivity in a subset of
Figure 5.  miR-221 promotes DNA damage.  (A) Alkaline
comet assay of T98G cells transfected with miR-ββ1 and
treated with TMZ for the indicated times. (B) Analysis of ȖHβAX
in T98G cells transfected with scrambled control miR or
miR-ββ1, treated with TMZ in the presence or in the absence of
MGMT cDNA, by immunocytofluorescence (upper and medium
panel) or by Western blot (lower panel). (C) Western blot
analysis of the indicated proteins upon transfection of T98G
cells with miR-ββ1 and MGMT cDNA and TMZ treatment for β4
hrs.
doi: 10.1γ71/journal.pone.0074466.g005
Figure 6.  Association of miR-221 and MGMT
expression.  Mann–Whitney U test analysis was performed to
evaluate the association between miR-ββ1 and MGMT
expression in long- and short -survival groups of patients. The
expression of miR-ββ1 (β^-Dct) (A-B) and MGMT (β^-Dct) are
inversely correlated with patient survival (p < 0.0490 and
p = 0.04γ, respectively).
doi: 10.1γ71/journal.pone.0074466.g006
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glioblastoma cell lines and primary cells obtained from GBM
patients. We found that the analyzed glioblastoma cell lines
(T98G, LN4β8, U87MG, and A17β) expressed different levels
of miR-ββ1/βββ and displayed a consistent difference in MGMT
expression. This inverse correlation was also observed in
glioblastoma biopsies.
Bioinformatics identified a possible miR-ββ1/βββ binding site
on MGMT. This was confirmed by a luciferase assay and
overexpression experiments. The effect of miR-ββ1/βββ on
MGMT levels was direct and not related to MGMT promoter
methylation, since miR transfection did not alter the MGMT
methylation profile. Instead, we found evidence that
miR-ββ1/βββ regulated MGMT levels, leading to increased
TMZ-induced apoptosis, reduced anchorage-independent
growth, and reduced cell viability. Overexpression of MGMT
cDNA with miR-ββ1/βββ rescued the effects on TMZ sensitivity.
This result was not restricted to glioma cells, but was obtained
also in other cancer cells sensitive to TMZ, such as human
malignant melanoma.
It has been demonstrated that MGMT may be a target also of
other miRs, such as miR-181, in GBM [β8]. Zhang et al.
demonstrated that miR-181d targets MGMT γ’ UTR, and
reported an inverse correlation between miR-181d and MGMT
levels in human GBM samples, in particular in those samples in
which the MGMT promoter was unmethylated [β8]. However,
the modest correlation between miR-181d and MGMT
suggested that other miRs may regulate MGMT expression.
Therefore, miR-ββ1/βββ may be part of this cohort.
MGMT expression may be regulated also thought the p5γ
pathway. Blough et al. provided evidence that p5γ regulates
MGMT expression in murine astrocytes, and presented data
suggesting that p5γ contributes to the regulation of MGMT
gene expression in the human astrocytic glioma cell line SF767
[β9].
In this manuscript, we demonstrate that miR-ββ1
overexpression increases DNA damage in glioma cells. In fact,
miR-ββ1-overexpressing glioma cells exhibited an increase in
DNA damage markers, such as P-ATM, P-p5γ, cleaved PARP,
and ȖHβAX. These markers were activated even in the
absence of TMZ, and became increased upon TMZ treatment.
MGMT participates in the repair of DNA. Thus, miR-ββ1/βββ
induces chronic MGMT downregulation, rendering the cells
unable to repair DNA damage. It is well established that
miRββ1/βββ are oncogenic microRNAs that are upregulated in
a number of human tumors [γ0,γ1,γβ]. In GMB tissue and cell
lines, upregulated miR-βββ and miR-ββ1 expression correlated
with the stage of the disease, cell motility, and TRAIL response
[19,βγ,γ1,γγ]. We found that miR-ββ1 is a negative prognostic
factor, since it is up regulated in short-survival patients and is
downregulated in long-survival ones. However, we did not
observe the expected correlation between miR-ββ1 expression
and response to temozolomide/survival. Arguably, overall
survival and therapy response have to be linked to other
factors. It therefore seems that the pro-oncogenic effect of
miR-ββ1 is more powerful than its potentiation of the response
to temozolomide.
The role of MGMT in DNA damage repair has been
investigated also in animal models. Reduced expression of this
repair enzyme has been thought to result in a spontaneous
‘mutator’ phenotype and to promote neoplastic lesions in the
presence of either endogenous or exogenous sources of
alkylation stress. Sakumi, et al. showed that Mgmt−/− mice
develop thymic lymphomas and lung adenomas to a greater
extent when exposed to methylnitrosourea (MNU), suggesting
that the DNA repair methyltransferase protected these mice
from MNU-induced tumorigenesis [γ4]. Sandercock et al.
reported that MGMT-deficient cells exhibited an increased
mutational burden, but only following exposure to specific
environmental mutagens [γ5]. Takagi et al. demonstrated that
mice with mutations in Mgmt as well as in the DNA mismatch
repair gene Mlh1 developed numerous tumors after being
administered MNU. When exposed to a sub-lethal dose of
MNU (1mM), the mutation frequency in Mgmt−/−/Mlh1−/− cells
was up to 1β times that of untreated cells; this effect was not
present in control mice [γ6]. Walter et al. generated transgenic
mice overexpressing MGMT in brain and liver, or in lung [γ7].
They found that expression of the transgene correlated with a
reduced prevalence of MNU-induced tumors in liver and in lung
and also with reduced spontaneous hepatocellular carcinoma.
Reese et al. found that overexpression of MGMT decreased
the incidence and increased the latency of thymic lymphoma
induction in mice with both heterozygous and wild type p5γ
alleles [γ8]. This protective effect was described also by Allay
et al., who reported that the incidence of lymphomas was much
lower in MGMT transgenic mice compared with controls [γ9].
Those studies thus suggest that MGMT, other than being
involved in the response to therapy, is also involved in DNA
repair. Therefore, its inactivation may produce devastating
effects on DNA integrity.
In summary, we have provided evidence of the existence of
an adjunct mechanism of MGMT regulation, besides promoter
methylation, involving miR targeting its γ’ UTR. We have also
shown that overexpression of miR-ββ1/βββ produces an
increase in sensitivity to TMZ via a reduction in the level of
MGMT. On the other hand, these miRs increase DNA damage,
conferring oncogenic features to glioma cells. This may link
miR-ββ1/βββ to poor GBM prognosis.
Supporting Information
Figure S1.  Methylation-specific PCR analyses for MGMT
methylation in glioblastoma human tumors. γγ glioblastoma
samples were used for analysis. The SW48 cell line and in vitro
methylated DNA (IVD) are shown as a positive control for
methylation, normal lymphocytes (NL) as a negative control for
methylation, and water (HβO) as a negative PCR control. U
and M indicate the presence of unmethylated or methylated
MGMT, respectively. Red colour is for methylated samples,
green for unmethylated and orange for undetermined samples.
(TIF)
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Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in
glioma cells
C Quintavalle1,2,7, E Donnarumma3,7, M Iaboni1,2, G Roscigno1,2, M Garofalo4, G Romano3, D Fiore1, P De Marinis5, CM Croce4
and G Condorelli1,2,6
Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in
treatments, survival of patients remains poor. To deﬁne novel pathways that regulate susceptibility to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) in glioma, we have performed genome-wide expression proﬁling of microRNAs (miRs). We show
that in TRAIL-resistant glioma cells, levels of different miRs are increased, and in particular, miR-30b/c and -21. We demonstrate that
these miRs impair TRAIL-dependent apoptosis by inhibiting the expression of key functional proteins. T98G-sensitive cells treated
with miR-21 or -30b/c become resistant to TRAIL. Furthermore, we demonstrate that miR-30b/c and miR-21 target respectively the
30 untranslated region of caspase-3 and TAp63 mRNAs, and that those proteins mediate some of the effects of miR-30 and -21 on
TRAIL resistance, even in human glioblastoma primary cells and in lung cancer cells. In conclusion, we show that high expression
levels of miR-21 and -30b/c are needed to maintain the TRAIL-resistant phenotype, thus making these miRs as promising
therapeutic targets for TRAIL resistance in glioma.
Oncogene advance online publication, 10 September 2012; doi:10.1038/onc.2012.410
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INTRODUCTION
Glioblastomas are the most common primary tumors of the brain
and are divided into four clinical grades on the basis of their
histology and prognosis.1 These tumors are highly invasive, very
aggressive and are one of the most incurable forms of cancer in
humans.2 The treatment strategies for this disease have not
changed appreciably for many years, and failure of treatment
occurs in the majority of patients owing to the strong resistant
phenotype. Therefore, the development of new therapeutic
strategies is necessary for this type of cancer.
A novel interesting therapeutic approach is the reactivation of
apoptosis using member of TNF (tumor necrosis factor)-family, of
which the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) holds the greatest interest. Apoptosis is a particularly
desirable treatment outcome, as it eradicates cancer cells without
causing a major inﬂammatory response, which could provide
unwanted survival signals. However, many cancers develop
functional defects in the drug-induced apoptosis pathway, which
may lead to constitutive or acquired resistance. To this end,
alternative pathways, such as the one activated by death
receptors including Fas/Apo-1, or DR4 (TRAIL-R1) and DR5
(TRAIL-R2), are being explored for cancer treatment. TRAIL is a
relatively new member of the TNF family, known to induce
apoptosis in a variety of cancers.3 Treatment with TRAIL induces
programmed cell death in a wide range of transformed cells, both
in vivo and in vitro, without producing signiﬁcant effects in normal
cells.3,4 Therefore, recombinant TRAIL or monoclonal antibodies
against its receptors (TRAIL-R1 and TRAIL-R2) are in phase II/III
clinical trials for different kinds of tumors, either as a single agent
or in combination with chemotherapy.5,6
However, a signiﬁcant proportion of human cancer cells are
resistant to TRAIL-induced apoptosis, and the mechanisms of
sensitization seem to differ among cell types. Different studies
relate resistance to TRAIL-induced cell death to downstream
factors. It has been shown that downregulation of two anti-
apoptotic proteins such as PED (Phosphoprotein enriched in
diabetes) or cellular-FLICE such as inhibitory protein (c-FLIP)
can sensitize cells to TRAIL-induced apoptosis.7–9 However the
mechanism of TRAIL resistance is still largely unknown.
miRs are a class of endogenous non-coding RNA of 19–24
nucleotides in length that has an important role in the negative
regulation of gene expression blocking translation or directly
cleaving the targeted mRNA.10 miRs are involved in the
pathogenesis of most cancers.10 In the last few years, our
understanding of the role of miRNA has expanded from the
initially identiﬁed functions in the development of round worms
to a highly expressed and ubiquitous regulators implicated in a
wide array of critical processes, including proliferation, cell death
and differentiation, metabolism and, importantly, tumorigenesis.11
We have recently showed an important role of microRNAs in TRAIL
sensitivity in non-small cell lung cancer (NSCLC).12–14
In this study, to identify novel mechanisms implicated in TRAIL
resistance in human glioma, we performed a genome-wide
expression proﬁling of miRs in different cell lines. We found
that miR-30b/c and -21 are markedly upregulated in TRAIL-
resistant, and downregulated in TRAIL-sensitive glioma cells.
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Our experiments indicate that miR-30b/c and -21 modulate TRAIL
sensitivity in glioma cells mainly by modulating caspase-3 and
TAp63 expression and TRAIL-induced caspase machinery.
RESULTS
Selection of TRAIL-sensitive vs TRAIL-resistant glioma cell lines
We analyzed TRAIL sensitivity of different human glioma cell lines.
Cells were exposed to TRAIL at two different concentrations for
24 h and cell death was assessed using the MTT assay (Figure 1a)
or propidium iodide staining (Figure 1b). As shown in Figure 1, we
can distinguish two sets of cells: TB10, LN229, U251 and U87MG
cells exhibited total or partial TRAIL resistance, whereas T98G and
LN18 cells underwent TRAIL-induced cell death.
miRs expression screening in TRAIL-resistant vs TRAIL-sensitive
glioma cell lines
To investigate the involvement of miRs in TRAIL resistance in
glioblastoma cell lines, we analyzed the miRs expression proﬁle in
the most TRAIL-resistant glioma cells (TB10 and LN229) vs the
TRAIL-sensitive cells (T98G and LN18). The analysis was performed
with a microarray chip containing 1150 miR probes, including 326
human and 249 mouse miRs, spotted in duplicates. Data obtained
indicated that seven miRs (miR-21, -30b, -30c, -181a, -181d, -146
and -125b) were signiﬁcantly overexpressed in resistant glioma
cells with at least 41.9-fold change (Table 1). Quantitative real-
time-polymerase chain reaction (qRT–PCR) validated the micro-
array analysis (data not shown).
Role of miRs in TRAIL resistance in glioma
To test the role of these overexpressed miRs in TRAIL sensitivity in
glioma, we transfected T98G TRAIL-sensitive cells with miR-21,
-30b, -30c, -181a, -146 and -125b. TRAIL sensitivity was evaluated
by MTT assay, propidium iodide staining and colony assay. We
obtained signiﬁcant results only for miR-30b/c and miR-21 that
were then extensively investigated. In fact, data obtained with
MTT assay and FACS analysis showed that the overexpression of
miR-30b/c and -21 was able to revert TRAIL sensitivity in T98G
(Figures 2a and b). Similar results were obtained in LN18 cells
(Figures 2c and d). This effect was not restricted to glioma, as
miR-30 and miR-21 were able to exert an anti-apoptotic action
also in non small cell lung cancer (NSCLC) (Supplementary
Figure 3B). We further evaluated TRAIL sensitivity by colony assay.
T98G and LN18 cells were transfected with miR-scrambled, miR-
30b/c and miR-21 for 48 h and then were treated with 50 or
100 ng/ml of superKiller TRAIL for 24 h. Cells were grown for 6 days
and then coloured with crystal violet-methanol solution
(Supplementary Figures 1A and B). The results indicated that
both miRs induced an increase of TRAIL resistance.
To further explore the role of miR-21 and -30b/c on TRAIL
sensitivity, we transfected U251 (Figure 3a) or LN229 (Figure 3b)
TRAIL-resistant cells with anti-miR-21, -30b, 30c, or with a
scrambled sequence. As shown in Figures 3a and b, transfection
of the anti-miR sequences was able to sensitize U251 and LN229
cells to TRAIL. Anti-miR-21 and -30c were also able to sensitize
to TRAIL the CALU-1-resistant non-small cell lung cancer (NSCLC)
TRAIL-resistant cell lines (Supplementary Figure 3C), indicating
that this effect was not restricted to glioma.
Identiﬁcation of cellular targets of miR-30b/c and miR-21
in glioma cells
To identify cellular targets of miR-30b/c and -21, we used as ﬁrst
attempt a bioinformatic search, using programs available on the
web including Pictar, TargetScan, miRanda and Microcosm target.
miR-21 targets different tumor suppressor genes and proteins
potentially involved in TRAIL resistance in glioblastoma
cells, such as PTEN (phosphatase and tensin homologue),
PDCD4 (programmed cell death 4), TPM1 (Tropomyosin 1) and
p53.15–17 Computer-assisted analysis identiﬁed the presence of
evolutionary-conserved binding sites for miR-21 in TAp63 gene.
We focused our attention on this p53 family member, as it
regulates the expression of TRAIL receptors and molecules
involved in TRAIL signaling.18 We also searched for miR-30
targets and among them we focused on caspase-3.
TRAIL-resistant and TRAIL-sensitive glioma or NSCLC cells
exhibited different levels of miR-21 and -30c assessed by either
qRT–PCR (Figure 4a and Supplementary Figure 3A) or by northern
blot analysis (Supplementary Figure 4). Interestingly, we observed
a reduction of protein (Figure 4b and Supplementary Figure 3D)
and mRNA (Figure 4c) levels of TAp63 and caspase-3 upon,
respectively, miR-21 or miR-30c and miR-30b (data not shown)
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Figure 1. TRAIL sensitivity of glioblastoma cells. Glioblastoma cell
lines (104 cell) were treated with superKiller TRAIL. After 24 h of
treatment, the effect on cell death was assessed with MTT assay
(a) or by propidium iodide staining and FACS analysis (b).
Table 1. microRNA identiﬁed in TRAIL-resistant glioma (LN229 and
TB10) compared with TRAIL-sensitive (T98G, LN18) cells
miR P-value Fold difference
hsa-miR-125b1-A 6.09e! 05 3.033
hsa-miR-30b-A 9.14e! 05 2.041
hsa-miR-30c-A 0.0001199 2.337
hsa-miR-146b-A 0.0001556 5.972
hsa-miR-181a-5p-A 0.0004698 2.66
hsa-miR-181d-A 0.0004817 3.035
hsa-miR-21-A 0.0032482 1.949
miRNA expression proﬁles in TRAIL-sensitive vs TRAIL-resistant cells.
miRNA screening was performed in triplicate for TRAIL-sensitive and
TRAIL-resistant cell lines by a microarray as described in Materials and
methods. A two-tailed, two-sample t-test was used (Po0.05). Seven
miRNAs were found to be signiﬁcantly deregulated in TRAIL-resistant cells
compared with the TRAIL sensitive.
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decrease in the levels of other caspases upon miR-30c transfection
(Figure 4b). On the contrary, TAp63 and caspase-3 protein levels
increased upon anti-miR-21 and anti-miR-30c transfection
(Figure 3c and Supplementary Figure 3D) in TRAIL-resistant cell
lines. To verify a direct link between the miR-21/TAp63 and miR-
30b/c and caspase-3, we performed luciferase assay by co-
transfecting pGL3-30 untranslated region (UTR) vectors along with
miR-21 or miR-30c. The results obtained indicated a direct
interaction of miR-21 with TAp63 and miR-30c with caspase-3
(Figure 4d). As indicated in Figure 4d, miR-30b and -30c have the
same seed sequence that recognizes caspase-3, differing only at
the latest four nucleotides of the 50. Therefore, miR-30b down-
regulates caspase-3 at the same extent than miR-30c (data not
shown). Deletions in seed complementary sites rescued the
repression of miR-21 and miR-30c on their identiﬁed targets
(Figure 4d).
Validation of miR-21 and miR-30b/c mechanisms of action
To demonstrate that miR-21 and miR-30b/c, by downregulating
TAp63 and caspase-3, are responsible for the TRAIL resistance
observed in T98G and LN18 cells, we transfected T98G with
caspase-3 or TAp63 complementary DNAs lacking the miRNA-
binding site in their 30UTR or with a control vector and miR-30c
(Figure 5a) or miR-21 (Figure 5b). Interestingly, transfection of
TAp63 and caspase-3 was able to overcome the effects of miR-21
and miR-30c, decreasing cell viability and increasing apoptosis
(Figures 5a and b). The data were conﬁrmed by colony assay in
T98G cells (Supplementary Figures 2A and B). Similar results were
obtained when we analyzed miR-30b (data not shown). These
rescue experiments proved the causative link between miR-21/
TAp63 and caspase-3/miR-30b/c and TRAIL sensitivity.
Effect of miR-21 and miR-30c expression on TRAIL sensitivity in
primary human glioma cell lines
MiR-21 and miR-30c expression levels were measured by qRT–PCR
in nine different human primary cell lines (Figure 6a), eight
derived from glioblastoma tumors (patient no. 1 to no. 8) and one
from tissue surrounding the tumor (patient no. 9), and compared
with TRAIL sensitivity. As shown in Figure 6b, TRAIL sensitivity
correlated with miR-21 and miR-30c expression levels in all cases
analyzed, with the exception of control sample that did not
respond to TRAIL. Moreover, anti-miRs expression in TRAIL-
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resistant primary cultured cells (patient no. 1 and no. 2) was able
to determine an increase of TRAIL sensitivity (Figure 6c) and
concomitantly an increase of the levels of TAp63 and caspase-3
(Figure 6d).
DISCUSSION
Sensitization of cancer cells to apoptosis could be a valuable
strategy to deﬁne new treatment options for cancer, in particular
when using agents that aim to directly activate apoptotic
pathways. A promising agent is the death receptor ligand TRAIL,19
as it induces apoptosis in most cancer cells, but not in normal
cells.20,21 Moreover, TRAIL exhibits potent tumoricidal activity
in vivo in several xenograft models, including malignant
glioma.22,23 Indeed, agonistic anti-TRAIL receptor monoclonal
antibodies (mAbs), including mapatumumab (HGS-ETR1, anti-
human DR4 mAb),24 lexatumumab (HGS-ETR2, anti-human DR5
mAb)25 and MD5-1 (anti-mouse DR5 mAb) are currently under
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intensive investigation. The former two mAbs have been tested in
phase 1 clinical trials in patients with systemic malignancy,
exhibiting excellent safety proﬁles. Anti-mouse DR5 mAb MD5-1
could also be administered safely without inducing hepatotoxicity
either alone or in combination with histone deacetylase inhibitors
in mice.26 The induction of apoptosis by TRAIL is essentially
dependent on the expression of speciﬁc TRAIL receptors and on
the activation of caspases,20 thus the regulation of the expression
levels of those molecules is of fundamental importance.
MicroRNAs are emerging as key regulators of multiple pathways
involved in cancer development and progression,27–29 and may
become the next targeted therapy in glioma. The present study
shows that microRNA expression may modulate TRAIL-induced
apoptosis in glioma cells, by the regulation of caspase-3 and
TAp63 levels. We analyzed the miRs proﬁle of TRAIL-resistant
compared with TRAIL-sensitive glioma cells. We then focused our
attention on miR-30b/c and miR-21, as only these miRs among
those identiﬁed by the array, demonstrated the ability to revert
the TRAIL-sensitive phenotype. We also provided evidences that
this regulation is not restricted to glioma, but it is present also in a
different type of cancer such as NSCLC.
MiR-21 has been found overexpressed in high-grade glioma
patients30 and studies have identiﬁed different miR-21 key targets
for glioma biology, such as RECK, TIMP3, Spry2 and Pdcd4 genes,
which are suppressors of malignancy and inhibitors of matrix
metalloproteinase.16,31–33 Moreover, levels of expression of miR-21
have been associated to patients survival.34
Other studies indicate that knockdown of miR-21 in cultured
glioblastoma cells triggers activation of caspases and leads to
increased apoptotic cell death.35 Corsten et al.36 hypothesized that
suppression of miR-21 might sensitize gliomas for cytotoxic tumor
therapy. With the use of locked nucleic acid (LNA)-anti-miR-21
oligonucleotides and neural precursor cells (NPC) expressing a
secretable variant of TRAIL (S-TRAIL), they showed that the
combined suppression of miR-21 and NPC-S-TRAIL leads to a
synergistic increase in caspase activity and a decreased cell
viability in human glioma cells in vitro and in vivo in xenograft
experiments. Interestingly, Papagiannakopoulos et al.15 described
that miR-21 targets multiple important components of the p53
tumor-suppressive pathways. They showed that downregulation
of miR-21 in glioblastoma cells leads to repression of growth,
increased apoptosis and cell cycle arrest, through the regulation of
target proteins such as HNRPK and TAp63. Our study describes for
the ﬁrst time the direct link between miR-21, TAp63 and TRAIL
sensitivity. We demonstrated that miR-21 targets the 30UTR
sequence of TAp63, and that transfection of miR-21 is able to
downregulate TAp63 at both mRNA and protein levels. More
importantly, we demonstrated that miR-21, through TAp63, is able
to modulate TRAIL sensitivity, as the co-transfection of miR-21 and
TAp63 cDNA renders the cells again responsive to TRAIL. TAp63 is
a transcription factor that regulates the expression levels of
different apoptosis-regulating genes, such as TRAIL receptors,
bcl2l11 and Apaf1.18 Thus, it is possible that those apoptosis-
regulating molecules are regulated by miR-21 through TAp63.
Several studies link miR-30 to apoptosis and human cancer.
Li et al.37 demonstrated that miR-30 family members inhibited
mitochondrial ﬁssion through the suppression of the expression
of p53 and its downstream target Drp1, whereas, Joglekar et al.38
demonstrated that miR-30 may have a role in epithelial-to-
mesenchymal transition. Our recent data demonstrate that miR-
30 targets the anti-apoptotic protein BIM, participating to
geﬁtinib resistance in lung cancer.39 MiR-30 has been also
associated with stem cell properties. Yu et al.40 described that
miR-30 is reduced in breast tumor stem cells (BT-ICs), and
demonstrated that enforced expression of miR-30 in BT-ICs
inhibits their self-renewal capacity by reducing Ubc9,
and induces apoptosis through silencing ITGB3. In our hands,
miR-30 overexpression inhibits TRAIL-induced apoptosis in
glioma cells by targeting caspase-3. In fact, modulating the
expression of either miR-30 or caspase-3, we observed a
modiﬁcation of TRAIL sensitivity of glioma cells. The opposing
results on the role of miR-30 on cell death may be ascribed either
to different cell system (breast vs glioma), or to different type of
cancer cell (stem vs differentiated cells). In favour of this
hypothesis, many reports describe opposing role of miRs in a
different cell contest.28 Recently, miR-30d has been described to
target caspase-3 in breast cancer cells, and thus to regulate
apoptosis.41 The seed sequence recognizing the 30UTR of
caspase-3 is highly homologous within the members of the
miR-30 family (miR-30b/c/d) suggesting a more generalized role
of miR-30 family members in the regulation of cell death and
cancer progression.
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Figure 6. Effect of miR-21 and 30c on primary glioblastoma cell lines. (a) qRT–PCR analysis of miR-21 and miR-30c levels in eight primary
glioblastoma cancer cell lines and one primary cell line derived from the surrounding tumor tissue used as control. (b) TRAIL sensitivity of
primary cell lines (104 cells) treated with two different doses of SuperKiller TRAIL for 24 h, as indicated. (c) Cell viability assay of glioblastoma
cells from two patients (#1 and #2) transfected with anti-miR-21 and anti-miR-30c and then treated with 50 ng/ml and 100 ng/ml of TRAIL
for 24 h. Anti-miRs treatment sensitized glioblastoma cells to TRAIL. (d) Western blot analysis of TAp63 and caspase-3 after anti-miR-21 and
anti-miR-30c transfection in patient #1 and #2.
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In many experiments, we observed that there is a redundancy
within miR-21 and miR-30 in the regulation of TRAIL sensitivity.
Our data, either in primary or in established cell lines,
demonstrates that it is sufﬁcient that one of the two miRs is
highly expressed in the cells, that apoptosis resistance will
manifest. We have also observed that miR-30 has a predominant
effect in contrasting TRAIL-induced apoptosis. This may be related
to the effect of this miR in targeting one important component of
the cell death machinery, that is, caspase-3.
In conclusion, our study analyzed microRNA expression pattern
in TRAIL-resistant and TRAIL-sensitive glioma cells, and identiﬁed
speciﬁc miRs and their targets involved in the regulation of the
apoptotic programme. This may be of relevance for future cancer
therapy improvement in glioma.
MATERIALS AND METHODS
Cell culture and transfection
U87MG, T98G, U251, TB10, CALU-1 and 293 cells were grown in Dulbecco’s
modiﬁed Eagle’s medium (DMEM). H460 were grown in RPMI. Media were
supplemented with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine and 100U/ml penicillin/streptomycin. LN229 and LN18 were
grown in Advanced DMEM (Invitrogen, Milan Italy)þ 2mM Glutamineþ 5%
fetal bovine serum. For miRs transient transfection, cells at 50% conﬂuency
were transfected using Oligofectamine (Invitrogen) with 100 nM of pre-miR-
30c, -30b, -125b, -146b, -181a, -21, miR-scrambled or anti-miR- (Applied
Biosystems, Milan, Italy). For caspase-3 and TAp63 transient transfection,
cells were transfected using Lipofectamine and Plus Reagent with 4 mg of
caspase-3 cDNA (Origene, Rockville, MD, USA) or TAp63 cDNA for 24 h.
TAp63 cDNA was obtained from Professor Viola Calabro` (Naples).
SuperKiller TRAIL for cell treatment was purchased from Enzo Biochem
(New York, NY, USA).
Primary cell cultures
Glioblastoma specimens were collected at neurosurgical Unit of Cardarelli
hospital (Naples). All the samples were collected according to a prior
consent of the donor before the collection, acquisition or use of human
tissue. To obtain the cells, samples were mechanically disaggregated, then
the lysates were grown in DMEM-F12 medium supplemented with 10%
fetal bovine serum 1% penicillin streptomicyn and 20 ng/ml EGF (Sigma-
Aldrich, Milan, Italy). To exclude a ﬁbroblast contamination, cells were
stained for GFAP, a protein found in glial cells.
Protein isolation and western blotting
Cells were washed twice in ice-cold phosphate-buffered saline, and lysed
in JS buffer (50mM HEPES pH 7.5 containing 150mM NaCl, 1% Glycerol, 1%
Triton X-100, 1.5mM MgCl2, 5mM EGTA, 1mM Na3VO4 and 1# protease
inhibitor cocktail). Protein concentration was determined by the Bradford
assay (Bio-Rad, Milan, Italy) using bovine serum albumin as the standard,
and equal amounts of proteins were analyzed by SDS–PAGE (12.5%
acrylamide). Gels were electroblotted onto nitrocellulose membranes
(Millipore, Bedford, MA, USA). For immunoblot experiments, membranes
were blocked for 1 h with 5% non-fat dry milk in Tris-buffered saline
containing 0.1% Tween-20, and incubated at 4 1C over night with primary
antibody. Detection was performed by peroxidase-conjugated secondary
antibodies using the enhanced chemiluminescence system (GE Healthcare,
Milan, Italy). Primary antibodies used were: anti-bActin from Sigma-Alrich;
anti-caspase-8, 9 and 10 were from Cell Signalling Technology (Boston, MA,
USA); anti-Caspase 3 and anti-TAp63 from Santa Cruz Biotechnologies
(Santa Cruz, CA, USA).
miRNA microarray experiments
From each sample, 5 mg of total RNA (from T98G, LN18, TB10, LN229 cells)
was reverse transcribed using biotin-end-labelled random-octamer oligo-
nucleotide primer. Hybridization of biotin-labelled cDNA was performed on
an Ohio State University custom miRNA microarray chip (OSU_CCC version
3.0), which contains 1150 miRNA probes, including 326 human and 249
mouse miRNA genes, spotted in duplicates. The hybridized chips were
washed and processed to detect biotin-containing transcripts by
streptavidin-Alexa647 conjugate and scanned on an Axon 4000B micro-
array scanner (Axon Instruments, Sunnyvale, CA, USA).
Raw data were normalized and analyzed with GENESPRING 7,2 software
(zcomSilicon Genetics, Redwood City, CA, USA). Expression data were
median-centered by using both the GENESPRING normalization option
and the global median normalization of the BIOCONDUCTOR package
(www.bioconductor.org) with similar results. Statistical comparisons were
done by using the GENESPRING ANOVA tool, predictive analysis of
microarray and the signiﬁcance analysis of microarray software (http://
www-stat.stanford.edu/Btibs/SAM/index.html).
RNA extraction and real-time PCR
Total RNAs (miRNA and mRNA) were extracted using Trizol (Invitrogen)
according to the manufacturer’s protocol. Reverse transcription of total
miRNA was performed starting from equal amounts of total RNA per
sample (1mg) using miScript reverse Transcription Kit (Qiagen, Milan, Italy),
for mRNASuperScript III Reverse Transcriptase (Invitrogen) was used. For
cultured cells, quantitative analysis of Caspase-3, Tap63, b-Actin (as an
internal reference), miR-30b/c, miR-21 and RNU5A (as an internal
reference) were performed by real-time PCR using speciﬁc primers
(Qiagen), miScript SYBR Green PCR Kit (Qiagen) and iQ SYBR Green
Supermix (Bio-Rad), respectively. The reaction for detection of mRNAs was
performed as follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 60 1C for 300
and 72 1C for 300 . The reaction for detection of miRNAs was performed as
follow: 95 1C for 150 , 40 cycles of 94 1C for 150 , 55 1C for 300 and 70 1C for
300 . All reactions were run in triplicate. The threshold cycle (CT) is deﬁned
as the fractional cycle number at which the ﬂuorescence passes the
ﬁxed threshold. For relative quantization, the 2(!DCT) method was used
as previously described.42 Experiments were carried out in triplicate
for each data point, and data analysis was performed by using software
(Bio-Rad).
Northern blot analysis
RNA samples (30mg) were separated by electrophoresis on 15%
acrylamide, 7mol/l urea gels (Bio-Rad, Hercules, CA, USA) and transferred
onto Hybond-Nþ membrane (Amersham Biosciences, Piscataway, NJ,
USA). Hybridization was performed at 37 1C in 7% SDS/0.2 mol/l Na2PO4
(pH 7.0) for 16 h. Membranes were washed at 42 1C, twice with 2#
standard saline phosphate (0.18mol/l NaCl/10mmol/l phosphate (pH 7.4)),
1 mmol/l EDTA (saline–sodium phosphate–EDTA; SSPE) and 0.1% SDS and
twice with 0.5# SSPE/0.1% SDS. The oligonucleotides (PRIMM, Milan, Italy)
used, complementary to the sequences of the mature miRNAs, were: miR-
21-probe 50-TCAACATCAGTCTGATAAGCTA-30 ; miR-30c-probe 50-GCTGAG
AGTGTAGGATGTTTACA-30 . An oligonucleotide complementary to the
U6 RNA (50-GCAGGGGCCATGCTAATCTTCTCTGTATCG-30) was used to
normalize the expression levels. Totally, 100 pmol of each probe were
end labelled with 50mCi [g-32P]ATP using the poly-nucleotide kinase
(Roche, Basel, Switzerland). Blots were stripped by boiling in 0.1% SDS for
10min before re-hybridization.
Luciferase assay
The 30 UTR of the human Caspase-3 genes was PCR ampliﬁed using the
following primers: Caspase-3 forward: 50-TCTAGAAGGGCGCCATCGCCAAG
TAAGAAA-30 , Caspase-3 reverse: 50-TCTAGACCCGTGAAATGTCATACTGA
CAG-30 and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega, Milan, Italy). A deletion was introduced into
the miRNA-binding sites by using the QuikChange Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) using the following: primers: Caspase-3
mut forward 50-GCAAAATTCTTAAGTATGTTATTTTCTGTTGAAATCAAAGGA
AAATAGTAATGTTTTATACT-30 . Caspase-3mut reverse 50-AGTATAAAACAT
TACTATTTTCCTTTGATTTCAACAGAAAATAACATACTTAAGAATTTTGC-30 .
The 30 UTR of the human TAp63 gene was PCR ampliﬁed using the
following primers: TAp63 forward: 50-TCTAGAGCAAGAGATAAGTCTTT
CATGGCTGCTG-30 , TAp63 reverse: 50-TCTAGATGGAAATCCCACTATCCCA
AG-30 , and cloned downstream of the Renilla luciferase stop codon in
pGL3 control vector (Promega). A deletion was introduced into the miRNA-
binding sites by using the QuikChange Mutagenesis Kit (Stratagene) using
the following: primers:TAp63 mut forward 50-CTGGTCAAGGGCTGTCATTG
CACTCCATTTTAATTT-30 TAp63 mut reverse 50-AAATTAAAATGGAGTGCAAT
GACAGCCCTTGACCAG-30 .
Hek-293 cells were cotransfected with 1.2mg of generated plasmid and
400mg of a Renilla luciferase expression construct pRL-TK (Promega) with
Lipofectamine 2000 (Invitrogen). Cells were harvested 24 h post transfec-
tion and assayed with Dual Luciferase Assay (Promega) according to the
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manufacturer’s instructions. Three independent experiments were per-
formed in triplicate.
Cell death quantiﬁcation
Cells were plated in 96-well plates in triplicate, stimulated and incubated
at 37 1C in a 5% CO2 incubator. SuperKiller TRAIL was used at ﬁnal
concentration of 50 or 100 ng/ml for 24 h. Apoptosis was analyzed via
propidium iodide incorporation in permeabilized cells by ﬂow cytometry.
The cells (2# 105) were washed in phosphate-buffered saline and
resuspended in 200ml of a solution containing 0.1% sodium citrate, 0.1%
Triton X-100 and 50 mg/ml propidium iodide (Sigma). Following incubation
at 4 1C for 30min in the dark, nuclei were analyzed with a Becton Dickinson
FACScan ﬂow cytometer (Becton Dickinson, Milan, Italy). Cellular debris
was excluded from analyses by raising the forward scatter threshold, and
the DNA content of the nuclei was registered on a logarithmic scale. The
percentage of elements in the hypodiploid region was calculated. Cell
viability was evaluated with the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s protocol.
Metabolically active cells were detected by adding 20ml of MTS to each
well. After 2 h of incubation, the plates were analyzed in a Multilabel
Counter (BioTek, Milan, Italy).
Colony assay
Cells were transfected with miR-scrambled, miR-30b/c or miR-21 for 24 h,
then were harvested and 2.4# 104 cells were plated in six-well plates. After
24 h, cells were treated with 50 or 100 ng/ml of superKiller TRAIL for 24 h,
as indicated. Cells were transferred to 100mm dishes and let grown for
6 days. Finally, the cells were coloured with 0.1% crystal violet dissolved in
25% methanol for 20min at 4 1C. Dishes were washed with water and then
let dry on the bench, and then photographs were taken.
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